Biochemical Assay Optimization and Computational Screening Efforts to Identify Potential LuxS Inhibitors by Wang, Keeshia Q
The University of San Francisco
USF Scholarship: a digital repository @ Gleeson Library |
Geschke Center
Master's Theses Theses, Dissertations, Capstones and Projects
Winter 12-13-2013
Biochemical Assay Optimization and
Computational Screening Efforts to Identify
Potential LuxS Inhibitors
Keeshia Q. Wang
University of San Francisco, keeshia.wang@gmail.com
Follow this and additional works at: https://repository.usfca.edu/thes
Part of the Amino Acids, Peptides, and Proteins Commons, Biochemical Phenomena,
Metabolism, and Nutrition Commons, Biochemistry Commons, Biotechnology Commons,
Enzymes and Coenzymes Commons, Medical Biochemistry Commons, Other Biochemistry,
Biophysics, and Structural Biology Commons, Other Chemicals and Drugs Commons, and the
Pharmaceutical Preparations Commons
This Thesis is brought to you for free and open access by the Theses, Dissertations, Capstones and Projects at USF Scholarship: a digital repository @
Gleeson Library | Geschke Center. It has been accepted for inclusion in Master's Theses by an authorized administrator of USF Scholarship: a digital
repository @ Gleeson Library | Geschke Center. For more information, please contact repository@usfca.edu.
Recommended Citation
Wang, Keeshia Q., "Biochemical Assay Optimization and Computational Screening Efforts to Identify Potential LuxS Inhibitors"
(2013). Master's Theses. 149.
https://repository.usfca.edu/thes/149
  
 
Biochemical Assay Optimization and Computational 
Screening Efforts to Identify Potential LuxS Inhibitors 
 
 
Thesis Presented to the Faculty of 
the University of San Francisco, Department of Chemistry 
for the Fulfillment of the Requirements for the Degree of 
Masters of Science in Chemistry 
 
 
Written By: 
Keeshia Soleil Q. Wang 
8/8/15!
!Biochemical Assay Optimization and Computational 
Screening Efforts to Identify Potential LuxS Inhibitors 
 
Thesis written by Keeshia Soleil Q. Wang 
This thesis is written under the guidance of the Faculty Advisory Committee and, 
approved by all its members, has been accepted in partial fulfillment requirements for 
the degree of 
 
Masters of Science in Chemistry 
at the University of San Francisco !!
 
 
 
 
 
Thesis Committee 
 
Megan E. Bolitho, Ph.D. 
Research Advisor 
 
Jie Jack Li, Ph.D. 
Associate Professor of Chemistry 
 
Lawrence Margerum, Ph.D. 
Professor of Chemistry !
Marcelo Camperi, Ph.D. 
Dean, College of Arts and Sciences !!
 
!Acknowledgements 
I would like to express my outmost gratitude to my mentor and advisor, Dr. Megan E. 
Bolitho.  I would like also to thank the rest of the faculty, staff, and graduate students at the 
University of San Francisco (USF), who have all supported me throughout my studies.  
Furthermore, I want to thank my family and friends who have always supported my 
aspiration in a career in science from the very beginning. 
 
My gratitude to Dr. Megan E. Bolitho for being an excellent mentor to myself as well as for 
being very understanding, kind, and patient throughout my research.  I thank her for believing 
in me and providing me with great guidance and mentoring as I conducted research in her lab.  
I would like to thank Dr. Larry Margerum for always being available to help whenever I 
needed it as well as taking the time to read and offer his suggestions in writing this thesis.  I 
also want to thank Dr. Jack Li for helping me in my search for job opportunities as well as 
reading and editing this thesis.   
 
To my family and friends, I want to thank you all for your unwavering support.  Thank you 
for standing by me through it all since I started my biochemistry degree as an undergraduate.  
To the new friends I made in San Francisco, I want to express my sincerest gratitude in 
making my experience as a graduate student as one the best in my life and one that I will 
never forget.   
 
 
!Table of Contents 
 
Chapter 1: Introduction .............................................................................................................. 1 
 1.1 S-Ribosylhomocysteinase (LuxS) .................................................................... 2 
 1.2 S-D-Ribosyl-L-homocysteine (SRH) ................................................................ 3 
 1.3 Biochemical Analysis of LuxS Activity .......................................................... 4 
  1.3.1 Co-BsLuxS-HT ................................................................................... 5 
  1.3.2 Ellman’s Assay ................................................................................... 6 
  1.3.3 Inhibition Assay .................................................................................. 7 
 1.4 Computational Screening ................................................................................. 8 
 1.5 Summary of Project Goals ............................................................................... 8 
 
Chapter 2: Materials and Methods ........................................................................................... 10 
 2.1 Purification of Co-BsLuxS-HT ...................................................................... 10 
  2.1.1 Chemical Reagents ........................................................................... 10 
  2.1.2 Biochemical Reagents, Kits, and Supplies ....................................... 10 
  2.1.3 Purification of Co-BsLuxS-HT ........................................................ 10 
  2.1.4 Preparation of Reagents .................................................................... 11 
  2.1.5 Protein Purification ........................................................................... 12 
  2.1.6 Determination of Protein Concentration by Bradford Assay ........... 14 
  2.1.7 Determination of Protein Concentration using NanoDrop  
   Spectrophotometer ND-1000 ............................................................ 15 
  2.1.8 SDS-PAGE ....................................................................................... 16 
 2.2 Computational Screening using DOCK Blaster ............................................ 16 
 2.3 Ellman’s Activity Assay ................................................................................ 18 
!  2.3.1 Chemical Reagents ........................................................................... 18 
  2.3.2 Preparation of Ellman’s Activity Assay Reagents ............................ 18 
  2.3.3 Ellman’s Activity Assay of Co-BsLuxS-HT .................................... 19 
  2.3.4 Kinetic Parameters Determination .................................................... 20 
 2.4 LuxS Inhibition Assay ................................................................................... 21 
  2.4.1 Chemical Reagents ........................................................................... 21 
  2.4.2 Preparation of LuxS Inhibition Assay Reagents ............................... 21 
  2.4.3 IC50 Determination for Selected Inhibitors ....................................... 23 
 
Chapter 3: Spectrophotometry ................................................................................................. 25 
 3.1 Spectrophotometers ....................................................................................... 25 
  3.1.1 PerkinElmer EnVision 2104 Multilabel Reader ............................... 26 
  3.1.2 NanoDrop Spectrophotometer .......................................................... 27 
  3.1.3 Agilent 8453 UV-Vis Spectrophotometer ........................................ 27 
 3.2 Spectrophotometric Assays ........................................................................... 28 
  3.2.1 Bradford Assay ................................................................................. 29 
  3.2.2 NanoDrop Spectrophotometer .......................................................... 30 
  3.2.3 Ellman’s Activity Assay ................................................................... 30 
 3.3 Application of Spectrophotometric Techniques to the Study of LuxS .......... 33 
 
Chapter 4: Purification of LuxS and Optimization of Activity Assay ..................................... 34 
 4.1 LuxS Purification ........................................................................................... 34 
  4.1.1 LuxS Overexpression and Cell Harvesting ....................................... 34 
  4.1.2 Cell Lysis .......................................................................................... 36 
!   4.1.2.1 French Press ............................................................ 36 
  4.1.3 Affinity Chromatography ................................................................. 37 
   4.1.3.1 Hand Column .......................................................... 37 
   4.1.3.2 ÄKTAprime Plus .................................................... 38 
 4.2 Determination of Co-BsLuxS-HT Enzyme Concentration ............................ 38 
  4.2.1 Bradford Assay ................................................................................. 39 
  4.2.2 NanoDrop ......................................................................................... 41 
 4.3 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
  (SDS-PAGE) .................................................................................................. 41 
  4.3.1 SDS-PAGE to Determine LuxS Purity ............................................. 42 
 4.4 Optimization of Ellman’s Assay for LuxS Activity ...................................... 43 
  4.4.1 Ellman’s Assay ................................................................................. 44 
  4.4.2 Kinetic Comparison .......................................................................... 45 
 4.5 Conclusion and Future Directions ................................................................. 46 
 
Chapter 5: Computational Screening for Potential Competitive Inhibitors ............................. 48 
 5.1 DOCK Blaster ................................................................................................ 49 
  5.1.1 General Guidelines ........................................................................... 50 
  5.1.2 Closed-form SRH vs. Open-form SRH ............................................ 50 
  5.1.3 RCSB Protein Data Bank (PDB) ...................................................... 51 
  5.1.4 Ligand Database ............................................................................... 53 
  5.1.5 Docking Visualization using PyMOL .............................................. 54 
 5.2 Docking Results ............................................................................................. 55 
  5.2.1 KEGG Database Results ................................................................... 59 
!   5.2.1.1 Initial Results .......................................................... 59 
   5.2.1.2 Second-Round Results ............................................ 61 
  5.2.2 Cayman Chemical Database Run Results ......................................... 62 
  5.2.3 FDA Database Run Results .............................................................. 63 
 5.3 Conclusion and Future Directions ................................................................. 64 
 
Chapter 6: Selection and in vitro Testing of Potential Competitive Inhibitors of LuxS .......... 66 
 6.1 Competitive Inhibition ................................................................................... 66 
  6.1.1 General Guidelines for Inhibition Assays ......................................... 67 
 6.2 DOCK Blaster Hit Categories ....................................................................... 67 
  6.2.1 Arginine-Based Structures ................................................................ 68 
   6.2.1.1 Similarity Structure Searches ................................. 69 
    6.2.1.1.1 SciFinder Similarity Searches ................... 69 
    6.2.1.1.2 Sigma-Aldrich Similarity Searches ........... 69 
    6.2.1.1.3 Other Structural Types .............................. 70 
 6.3 Assays of Selected Compounds ..................................................................... 70 
  6.3.1 Argininosuccinate and Similar Structures ........................................ 71 
   6.3.1.1  Argininosuccinate ................................................... 71 
   6.3.1.2  NG-Methyl-L-arginine acetate salt .......................... 74 
   6.3.1.3  NG, NG- Dimethylarginine dihydrochloride ............ 78 
   6.3.1.4  Succinic Acid .......................................................... 81 
   6.3.1.5  L-Arginine hydrochloride ....................................... 84 
  6.3.2 Other Arginine-Based Structures ...................................................... 87 
   6.3.2.1  N-Nitro-L-arginine ................................................. 87 
!   6.3.2.2  L-Nitroarginine methyl ester  
     hydrochloride (L-NAME) ...................................... 90 
  6.3.3 Other Amino Acids ........................................................................... 93 
   6.3.3.1  L-Glutamine ........................................................... 93 
   6.3.3.2  L-Lysine monohydrochloride ................................. 96 
   6.3.3.3  DL-Asparagine ....................................................... 99 
  6.3.4 Other Structural Types .................................................................... 102 
 6.4 Determination of IC50 .................................................................................. 105 
  6.4.1 Argininosuccinate ........................................................................... 105 
  6.4.2 L-Nitroarginine Methyl Ester Hydrochloride (L-NAME) .............. 106 
 6.5 Conclusion and Future Directions ............................................................... 107 
References .............................................................................................................................. 108 
Appendix A: DOCK Blaster Screening Runs ........................................................................ 110 
Appendix B: LuxS Inhibition Assays .................................................................................... 154 
Appendix C: Sample Preparation Calculation ....................................................................... 190 
Appendix D: Sample Activity Calculation for Ellman’s and Inhibition Assays ................... 191 
   
 
 
 
 
 
 
 
!List of Figures 
1.1 Quorum Sensing and Disease ....................................................................................... 1 
1.2 LuxS Inhibitors ............................................................................................................. 2 
1.1.1 LuxS .............................................................................................................................. 3 
1.2.1 SRH Structural Variants ............................................................................................... 3 
1.2.2 SRH Structural Variants Bound to LuxS ...................................................................... 4 
1.3.1 pET22b(+) vector .......................................................................................................... 5 
1.3.2 Ellman’s Assay for LuxS Activity ................................................................................ 6 
1.3.3 Competitive Inhibition .................................................................................................. 8 
3.1.1 EnVision Plate Reader ................................................................................................ 26 
3.1.2 NanoDrop Spectrophotometer .................................................................................... 27 
3.1.3 UV-Vis Spectrophotometer ........................................................................................ 28 
3.2.3 Michaelis-Menten Graph ............................................................................................ 32 
4.1.2.1 French Press ................................................................................................................ 37 
4.2.1 Bradford Assay ........................................................................................................... 39 
4.3.1 SDS-PAGE ................................................................................................................. 42 
4.4.2 Kinetic Comparison .................................................................................................... 46 
5 DOCK Blaster Computational Screening Method ...................................................... 49 
5.1.1 DOCK Blaster Scoring ............................................................................................... 50 
5.1.2 Different Forms of SRH ............................................................................................. 51 
5.1.3 PDB Codes .................................................................................................................. 53 
6.3.1.1 Argininosuccinate Inhibition Assay ............................................................................ 72 
6.3.1.2 NG-Methyl-L-arginine acetate salt (L-NMMA) Inhibition Assay .............................. 75 
6.3.1.3 NG, NG- Dimethylarginine dihydrochloride Inhibition Assay .................................... 79 
!6.3.1.4 Succinic Acid Inhibition Assay .................................................................................. 82 
6.3.1.5 L-Arginine hydrochloride Inhibition Assay ............................................................... 85 
6.3.2.1 N-Nitro-L-arginine Inhibition Assay .......................................................................... 88 
6.3.2.2 L-Nitroarginine methyl ester hydrochloride (L-NAME) Inhibition Assay ................ 91 
6.3.3.1 L-Glutamine Inhibition Assay .................................................................................... 94 
6.3.3.2 L-Lysine monohydrochloride Inhibition Assay .......................................................... 97 
6.3.3.3 DL-Asparagine Inhibition Assay .............................................................................. 100 
6.3.4.1 Sulfasalazine Inhibition Assay .................................................................................. 103 
6.4.1 Argininosuccinate IC50 Determination ..................................................................... 105 
6.4.2 L-NAME IC50 Determination ................................................................................... 106 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!List of Tables 
2.1.6  Bradford Assay Standards ............................................................................. 15 
2.3.3  Ellman’s Activity Assay ................................................................................ 20 
2.4.2  Ellman’s Inhibition Assay ............................................................................. 23 
2.4.3  Determination of IC50 Values ........................................................................ 24 
4.1.2  Representative OD600 values for LuxS overexpression cultures .................... 36 
4.2.2  NanoDrop Concentration Data ...................................................................... 41 
5.2  1JVI vs. 1YCL ............................................................................................... 56 
5.2.1.1  Initial Results ................................................................................................. 61 
5.2.1.2  Second-Round Results ................................................................................... 62 
5.2.2  Cayman Chemical Database Run Results ...................................................... 63 
5.2.3  FDA Database Run Results ........................................................................... 64 
6.2.1  Arginine-Based Structures ............................................................................. 68 
6.2.1.1.1 SciFinder Similarity Search ........................................................................... 69 
6.2.1.1.2 Sigma-Aldrich Similarity Search ................................................................... 69 
6.2.1.1.3 Other Structural Types ................................................................................... 70 
 
         
 
 
 
  !! !
!Abstract 
 Quorum!sensing!(QS)!is!a!process!of!coordination!of!bacterial!gene!expression!in!response!to!cell!population.! !System!two!QS! is!regulated!by!the!small!signaling!molecule! autoinducer<2! (AI<2)! and! is! implicated! in! the! infectious! behaviors! of!various! bacterial! species.! ! AI<2! is! biosynthesized! from! S"ribosylhomocysteine!(SRH)!by!the!enzyme!LuxS!and!induces!interspecies!cell<to<cell!communication.!!Inhibition!of!LuxS!would!therefore!inhibit!interspecies!QS.! !Herein,!a!search!for!novel! molecular! species! that! will! competitively! bind! with! SRH! in! the! LuxS!binding! site! is! performed! in% silico.! ! Computational! screening! results! are! then!validated!in%vitro!using!an!optimized!LuxS!inhibition!assay.!!!!
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Chapter 1: Introduction 
 
Quorum sensing (QS) is a process of coordination of bacterial gene expression in response to 
cell population. There are two different quorum sensing (QS) systems.  System One quorum 
sensing is regulated by a class of signaling molecules called autoinducer-1 (AI-1) and is 
involved in intraspecies communication, occurring only within one species.  System Two 
quorum sensing is regulated by a small signaling molecule called autoinducer-2 (AI-2).  AI-2 
is synthesized from S-D-ribosyl-L-homocysteine (SRH) by the enzyme LuxS and induces 
interspecies cell-to-cell communication in many human pathogens.1–3 AI-2 is implicated in 
the infectious behaviors of various bacteria that cause a range of human diseases, including 
those shown in Figure 1.1.4  Inhibition of LuxS would thereby potentially inhibit interspecies 
quorum sensing.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 | Quorum Sensing and Disease.  List of bacterial infections involved in quorum sensing 
that directly affects humans in different areas of the anatomy.4 
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Currently, a number of inhibitors of LuxS have already been discovered.  Many of these 
inhibitors, such as (S)-2-amino-4-(((2S,3R)-2,3-dihydroxy-4-(hydroxyamino)-4-
oxobutyl)thio)butanoic acid reported by Wnuk et al. that imitate the physical traits of SRH, 
were developed by a rational design approach (Figure 1.2).1  Another type of LuxS inhibitor 
that has also been reported was discovered in nature, which is the brominated furanone 
(Figure 1.2).2 The unique structure of the brominated furanone as a competitive inhibitor of 
LuxS gave the idea for the discovery of more “non-SRH analogs” for LuxS inhibition.  
Herein, a search for novel molecular species that will competitively bind with SRH in the 
LuxS binding site is performed in silico.  The program used for the search for these novel 
LuxS inhibitors is DOCK Blaster.  The in silico results are then tested to determine whether 
LuxS activity is inhibited in vitro using an optimized LuxS inhibition assay.3 
 
SRH Analog      Non-SRH Analog 
                             
Figure 1.2 | LuxS Inhibitors.  Examples of the two different types of known LuxS inhibitors.  The 
SRH analog (S)-2-amino-4-(((2S,3R)-2,3-dihydroxy-4-(hydroxyamino)-4-oxobutyl)thio)butanoic acid 
reported by Wnuk et al. is an example of rationally-designed LuxS inhibitor.1 The non-SRH analog, a 
brominated furanone, is the inspiration for the search for more non-SRH analogs of LuxS in silico.2 
 
 
1.1 | S-Ribosylhomocysteinase (LuxS).   The LuxS enzyme from the bacterium Bacillus 
subtilis is a homodimer.  Its activity is greatly dependent on the appropriate binding of its 
substrate, S-D-ribosyl-L-homocysteine (SRH) to key amino acids.  LuxS contains a Fe2+ metal 
ion as a cofactor (and not a Zn2+ cofactor that was previously reported), which is connected to 
HO S N
H
OO
NH2 OH
OH
OH
O
Br
Br
O
! 3 
a water molecule tetrahedrally with the residues His-54, His-58, and Cys-126.5,6  Although 
LuxS was determined to be a Fe2+–containing protein in nature, the enzyme also functions 
with Co2+ as its metal cofactor in vitro.5–9  
 
 
 
 
 
 
 
 
 
Figure 1.1.1 | LuxS.  The X-ray crystal structure of the LuxS homodimer enzyme from B. subtilis with 
a cobalt cofactor (Co-BsLuxS) containing S-ribosylhomocysteine (SRH).6  Its molecular weight is 
approximately 36 kDa. 
 
 
1.2 | S-D-Ribosyl-L-homocysteine (SRH).  S-D-Ribosyl-L-homocysteine (SRH) is the 
substrate for the LuxS enzyme. In solution, SRH can take on one of two forms: a cyclic 
(closed-form) or linear (open-form; Figure 1.2.1). Both of these variants were studied and 
used for the docking of the enzyme Co-BsLuxS-HT.    
                                             
                         Closed-SRH      Open-SRH 
Figure 1.2.1 | SRH Structural Variants. S-D-Ribosyl-L-homocysteine (SRH) can exist in either of 
two structural forms. 
O
S
OHOH
OH
R
OH
S
OH O
OHH
HR
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LuxS crystal structures bound to both the cyclic and linear forms of SRH may be found in the 
Protein Data Bank (PDB): structure 1JVI has cyclic SRH bound, and structure 1YCL has the 
2-ketone intermediate (of the SRH to AI-2 reaction) bound.5,6  Both forms were used for 
docking because, according to Huang et al., SRH may bind to the LuxS enzyme when its 
ribosyl moiety is in either its α- and β-SRH form or as a linear aldose.  The binding of α-SRH 
is more thermodynamically preferred because of its low binding energy requirement of 47.5 
kJ/mol, which is then followed by the β-SRH.  The ring-opening process resulting in the 2-
keto-SRH intermediate was due in part by the assisted ring opening by H2O at the active 
site.5,6,8 
 
     
 
 
Figure 1.2.2 | SRH variants bound to LuxS.  Image of the 1JVI (left) and 1YCL (right) BsLuxS 
crystal structures showing the open and closed representation forms of SRH bound in each active site.  
Picture was obtained using PyMOL. 
 
1.3 | Biochemical Analysis of LuxS Activity.  The activity of the Co-BsLuxS-HT can be 
monitored using a biochemical assay called the Ellman’s assay.  It is a colorimetric assay that 
monitors free thiols in solution by producing a yellow color in the presence of such thiols.1,3,10 
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1.3.1 | Co-BsLuxS-HT.  The enzyme LuxS is a homodimeric enzyme responsible for the 
production of autoinducer-2. The enzyme Co-BsLuxS-HT was isolated from the bacterium 
Bacillus subtilis (B. subtilis), whose protein-specific sequence was inserted into the 
Escherichia coli (E. coli) pET22b(+) vector.  The pET22b(+) vector has a C-terminal six-
histidine tag sequence and an ampicillin resistance marker. This plasmid came to be 
eventually known as ELS1409, which was provided by the Bassler lab (Princeton 
University). The isolated vector was freshly transformed into BL21[DE3] Gold competent 
cells for the expression of the Co-BsLuxS-HT protein.  Since the vector has an ampicillin 
marker, all bacterial cultures were grown with 75 mg/mL ampicillin so that the only bacteria 
able to grow were those with ampicillin resistance.  The Co-BsLuxS-HT protein isolated 
from the bacterial growth was then purified using a cobalt column because the six-histidine 
tag has an affinity for cobalt.5,10   
 
 
 
 
 
 
 
 
 
 
Figure 1.3.1 | pET22b(+) vector.  The plasmid pET22b(+) was used to insert the DNA sequence that 
is to be used for the expression of the Co-BsLuxS-HT protein.  (a) Vector region of DNA encoding B. 
subtilis LuxS (b) C-terminus six-histidine residues (c) Ampicillin marker and (d) location of the 
lacI repressor gene.11  
 
!
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1.3.2 | Ellman’s Assay.  The Ellman’s assay is generally used for the quantification of free 
thiols in a solution.  The thiols react with Ellman’s reagent 5,5'-dithiobis-(2-nitrobenzoic 
acid) (DTNB), which undergoes a disulfide bond exchange with a thiol molecule and forms 
the product 2-nitro-5-thiobenzoate (NTB-), which has a yellow color.  During the 
performance of the assay, the yellow product is monitored at 412 nm using the UV–Vis 
spectrophotometer.1,3,7,9 For LuxS, the Ellman’s assay is used to indirectly determine how 
much autoinducer-2 is produced. SRH binds to the LuxS enzyme and produces DPD (the AI-
2 precursor) and homocysteine at a 1:1 ratio.  The homocysteine is then converted into a 
disulfide conjugate of homocysteine and DTNB, and the yellow product 2-nitro-5-
thiobenzoate is monitored at 412 nm.  Since the 2-nitro-5-thiobenzoate is produced at a 1:1 
ratio with DPD, for every one 2-nitro-5-thiobenzoate produced, one autoinducer-2 is also 
produced.1,10,12  
 
 
Figure 1.3.2 | Ellman’s Assay for LuxS Activity.  The Ellman’s assay reaction from the conversion 
of SRH to DPD and homocysteine by the enzyme LuxS.  Homocysteine reacts with DTNB to produce 
the yellow colored product, 2-nitro-5-thiobenzoate.  Its production is at a 1:1 ratio with DPD; hence 
one autoinducer-2 is also produced.5,12,13 
 
DPD : 2-nitro-5-thiobenzoate 
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1.3.3 | Inhibition Assay.  The type of inhibition that is the focus of this project is reversible 
inhibition.  Reversible inhibition of an enzyme may occur in many different ways.  The three 
types of reversible inhibition are uncompetitive, non-competitive, and competitive inhibition.  
Uncompetitive inhibition is when the inhibitor binds to a different site other than the enzyme 
active site so that it does not compete or interfere with the binding of the substrate and only 
occurs when the enzyme–substrate complex has been formed.  Non-competitive inhibition 
binds also at a site different from the enzyme active site.  However, when the inhibitor is 
bound, it alters the enzyme conformation and reshapes the active site, which does not allow 
for full functionality.  Competitive inhibition is defined as a substrate having equal or greater 
affinity than the substrate for the enzyme active site.  The inhibitor competitively competes 
with the substrate for the enzyme active site.  The reason why competitive inhibitors were 
chosen over other types of inhibitors for this project is because most drugs that are currently 
produced are competitive inhibitors.  Furthermore, competitive inhibitors are more 
straightforward to evaluate in vitro.14 Increasing concentrations of the inhibitor are added to 
the Ellman’s assay with a constant substrate (SRH) concentration.1–3  As the concentration of 
inhibitor increases, it is less likely for the substrate to compete for the active site, which 
ultimately decreases the enzyme activity.  
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Figure 1.3.3 | Competitive Inhibition.  Above is an illustration of what is hoped to be accomplished 
by discovering potential new competitive inhibitors.  Without any presence of an inhibitor the substrate 
can bind to enzyme active and react to form products without any disruption.  However, when as an 
increase amount of competitive inhibitor is added, the rate of reaction should start to decrease, but this 
is dependent upon how potent the inhibitor is.1-3,14 (Figure modified from Reference 14.) 
 
 
1.4 | Computational Screening.  Computational screening is an increasingly widely used 
method for the discovery of new potential enzyme inhibitors. The program used is called 
DOCK Blaster.15,16 The PDB code of an enzyme can be input into the DOCK Blaster program 
and docked with a selected database of small molecules that is provided by the program.  The 
results are then viewed on PyMOL to check whether the potential inhibitors are indeed 
docked into the enzyme active site.15,17  If so, an in vitro inhibition assay is then performed to 
validate the activity of each computational “hit” and to check the potency of the inhibitor.   
 
 
1.5 | Summary of Project Goals.  The goal of the project is to use the DOCK Blaster 
computational screening platform to discover new potential inhibitors that would 
competitively bind to the LuxS enzyme active sites, and then to validate the activity of these 
compounds using an optimized Ellman’s assay.  The discovery of competitive inhibitors of 
! 9 
LuxS is of great importance because of their potential to inhibit system-2 quorum sensing.  
Since system-2 quorum sensing is involved in interspecies communication of bacteria in 
many human pathogens, inhibiting the reaction that produces autoinducer-2 that is involved 
in signaling communication amongst the bacteria is an ultimate goal for potential therapeutic 
drugs.  First, an optimization of the Ellman’s assay for the eventual biochemical evaluation of 
potential inhibitors was achieved (Chapter 4). Second, various parameters for the DOCK 
Blaster computational screening program, including the choice of a suitable LuxS crystal 
structure (1JVI), were investigated. A number of computational screening runs were 
executed, with the predicted binding interactions of “hit” compounds visualized using PyMol 
(Chapter 5). A subset of compounds predicted to bind with high affinity to the LuxS active 
site was then evaluated using the Ellman’s assay to determine whether or not these 
compounds truly inhibited LuxS in vitro (Chapter 6).
! 10 
Chapter 2: Materials and Methods 
 
2.1 | Purification of Co-BsLuxS-HT.  The purification of the Co-BsLuxS-HT enzyme is 
modified from literature reports as discussed below.7,10 
 
 
2.1.1 | Chemical Reagents.  Cobalt chloride (CoCl2), sodium chloride (NaCl), ethanol, 
manganese chloride (MnCl2), borate (H3BO3), ammonium molybdate ((NH4)6Mo7O24), 
copper sulfate (CuSO4), hydrogen chloride (HCl), D-glucose, ammonium sulfate 
[(NH4)2SO4], potassium phosphate dibasic (KH2PO4), and potassium phosphate monobasic 
(K2HPO4) were purchased from commercial vendors.  
 
 
2.1.2 | Biochemical Reagents, Kits, and Supplies.  Casamino acids and LB agar were 
purchased from BioWorld.  BL21[DE3] Gold competent cells were purchased from Agilent 
Technologies. Ampicillin sodium salt and the vacuum filtration systems were purchased from 
VWR. 5 mL cobalt columns were purchased from GE Healthcare. TALON® Resin was 
purchased from Clontech laboratories. PageBlue™ protein staining solution, Tris EDTA (TE) 
buffer, PageRuler™ plus prestained protein ladder, bovine serum albumin (BSA) standard 
kit, and Bradford dye were purchased from Fermentas.   
 
 
2.1.3 | Purification of Co-BsLuxS-HT.  The purification of Co-BsLuxS-HT enzyme was 
originally described in the literature by Pei et al.7  Modifications to this literature procedure 
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were implemented to optimize LuxS production, including the use of French press and the 
ÄKTAprime Plus protein purification system.10 
 
 
2.1.4 | Preparation of Reagents.  The reagents required for the purification of the Co-
BsLuxS-HT enzyme are prepared as directed: (A) Co-BsLuxS-HT Minimal Media (1 L). 
First, 1000X trace metals solution was prepared by adding 500 mM MgSO4, 0.5 mM NaCl, 
0.1 mM MnCl2, 0.5 mM H3BO3, 1 µM (NH4)6Mo7BO3, and 10 µM CuSO4 into 10 mL of 0.1 
M HCl. The solution was then filtered through a Stericup.  The 100X sugar stock solution 
was prepared by adding 25% D-glucose and 10% (NH4)2SO4 in hot distilled water.  Then, 
once the solution was warm to the touch, 200 µg/mL thiamin and 100 µg/mL D-biotin were 
added into a final volume of 500 mL distilled water and filtered through a Stericup. For the 
preparation of 1 L LuxS minimal media, 5.5 g KH2PO4, 10.8 g K2HPO4, 10 g NaCl, and 5 g 
casamino acids were mixed into 989 mL distilled water. Then, 1 mL of 1000X trace metals 
stock solution and 10 mL of 100X sugar stock solution were added to the solution. The media 
was then filtered through a 0.45 µM pore size Stericup. (B) LB Amp75 Media (1 L). To 800 
mL H2O was added 10 g bacto-tryptone, 5 g yeast extract, 10 g NaCl.  Then, the pH was 
adjusted to 7.5 with NaOH with a final volume of 1 L and autoclaved for 15 min. at 121 °C.  
After media has cooled, 750 µL of 100 mg/mL ampicillin was added to the media for a final 
antibiotic concentration of 75 mg/mL. (C) 100 mM CoCl2 (50 mL). 0.65 g of CoCl2 was 
added to 50 mL distilled water and stored at room temperature for future use.  (D) 100 mM 
Isopropyl β-D-1-thiogalactopyranoside/IPTG (50 mL). 1.19 g of IPTG was added to 50 mL 
of distilled water and mixed on a magnetic stirrer. 1 mL aliquots were prepared and kept at    
–80 °C for future use. (E) Preparation of the Bacterial Glycerol Stocks. To prepare bacterial 
glycerol stocks, 750 µL of the bacterial cultures grown in LB Amp75 media were added to 
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250 µL of 80% glycerol in a 1.5 mL Eppendorf tube and quick-frozen with liquid nitrogen 
and stored for future use. (F) Buffers. Preparation of binding buffer included the addition of 
50 mM sodium phosphate, 300 mM NaCl, and adjusting the pH to 7.4 with a final buffer 
volume of 1 L.  For preparation of mechanical lysis buffer, a solution of 20 mM Tris·HCl (pH 
8.0), 500 mM NaCl, and 5 mM imidazole (pH 8.0) was prepared. The Elution Buffer (EB) 
was made consisting of 20 mM Tris·HCl (pH 8.0), 500 mM NaCl, 150 mM imidazole (pH 
8.0). For the preparation of 10X running buffer, 30.3 g of trizma base, 144.0 g of glycine, and 
10 g of SDS were dissolved and mixed into 1 L of distilled water. (G) Preparation of 12.5% 
SDS-PAGE Gels. To make a 12.5% gel, a stacking gel solution and a separating gel solution 
were made. For preparation of the separating gel solution, 3.35 mL of distilled water, 2.5 mL 
of 1.5 M Tris·HCl (pH 8.8), 55 µL of 20% SDS, 4 mL of Acrylamide/Bis, 80 µL of 10% 
ammonium persulfate (APS) were added. 8 µL of tetramethylethylenediamine (TEMED) was 
added last. For the stacking gel solution, 6.1 mL of distilled water, 2.5 mL of 0.5 M Tris·HCl 
(pH 6.8), 55 µL of 20% SDS, 1.3 mL of 30% Acrylamide/Bis, 80 µL of 10% APS were 
added. 8 µL of TEMED was added last. Bio-Rad Mini-PROTEAN® Tetra handcast gel frame 
for two gels was set up.  First the separating gel solution was poured up to 3/4th height of the 
gel frame and allowed to solidify. Isopropanol was immediately added to level the surface of 
the gel.  After the gel has solidified (as could be seen from the leftover solution) the 
isopropanol was removed. The stacking gel was then added into the remaining space and 
combs were placed at the top of the gel frame. Once the gel has solidified, it was stored in the 
refrigerator by wrapping it in wet paper towels and keeping it in a Ziploc bag. 
 
 
 
2.1.5 | Protein Purification.  A 5 mL LB Amp75 media starter culture containing the E. coli 
BL21 bacterial cells freshly transformed with plasmid ELS1409 was grown overnight for 
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approximately 16 h at 37 °C.  The 5 mL starter culture was then back-diluted 1:1000 into 50 
mL minimal Amp75 media and grown for 16 h at 37°C.  The 50 mL culture in turn was back-
diluted 1:50 into 2 L of minimal Amp75 media and grown until its OD600 has reached ~0.6 at 
37 °C.  Final concentration of 200 µM CoCl2 was then added to the culture and incubated for 
30 min. at 30 °C. After 30 min., the cultures were induced with final concentration 100 µM 
IPTG.  The cultures were incubated with shaking for another 16 h at 30 °C.  After 16 h, the 
pellet of cells was collected by centrifugation of the media at 5000 rpm and a temperature of 
4 °C.  The pellet was resuspended in 35 mL mechanical lysis buffer. The resuspended cells 
were lysed via French press at approximately 20,000 psi and then centrifuged at 5000 rpm in 
order to retrieve the supernatant that contains the Co-BsLuxS-HT protein. The supernantant 
containing the Co-BsLuxS-HT protein was sequentially filtered using 5.0 µM, 0.8 µM, and 
0.2 µM filter units in order to make certain that the column will not clog because of the 
denseness of the supernatant. The Co-BsLuxS-HT protein was purified using a 5 mL 
TALON® Crude HiTrap, which was connected to run using the ÄKTAprime plus protein 
purification system.  The 5 mL Talon® Crude HiTrap was initially equilibrated with 5 column 
volumes (CV) of Binding Buffer.  The ÄKTA contains already set programs for affinity 
columns, which was used for the purification of the Co-BsLuxS-HT protein.  The “Affinity 
Gradient Step” was chosen from “Methods Template” on the ÄKTA.  The template was 
programmed line-by-line in accordance to the template.  First, set sample injected by “pump”.  
Pressure limit is set to 0.5 MPa, flow rate is set to 4 mL/min, and the fraction size is set to 1 
mL.  The equilibration volume is set to 3 CV because the column was initially already 
equilibrated with 5 CV during the cleaning process.  The sample inject volume used is 
dependent upon the amount of protein supernatant left from the filtration with the addition of 
5 mL of extra volume using the binding volume after the only very little protein supernatant 
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has already been pumped into the system.  Then, the “wash 1” volume is set to 5 CV and the 
elution volume is set to another 5 CV.  No “wash 2” volume is needed and therefore, when 
asked if method is ready, “yes” was selected.  The Co-BsLuxS-HT protein (colored purple) 
was eluted out automatically and fractions 4–12 was collected based on the peak.10 The 
concentration of the protein was determined by measuring the absorbance of each fraction 
using the NanoDrop Spectrophotometer ND-1000.  The Abs. 1% is set to 6.23, which was 
determined from the LuxS sequence using the ExPASy ProtParam tool.  Then, some fractions 
were eliminated based on the amount of Co-BsLuxS-HT needed to perform the LuxS 
inhibition assay (160 µM working solution required).  Fractions containing sufficient LuxS 
were pooled and a triplicate NanoDrop concentration reading taken.  Then, 80 µL of 
combined fractions were then aliquoted into 1.5 mL Eppendorf tubes and stored for future use 
in the performance of activity assays and inhibition assays. 
 
 
2.1.6 | Determination of Protein Concentration by Bradford Assay.  Initially the 
concentration of Co-BsLuxS-HT was determined by Bradford assay.18 Bradford assay is a 
colorimetric protein assay that measures the Coomassie Brilliant Blue G-250 dye that binds to 
the protein at 595 nm.  In order to measure the concentration of the Co-BsLuxS-HT proteins, a 
standard curve run was done using different concentrations of bovine serum albumin (BSA).  
The BSA standard values can be seen below (Table 2.1.6).   Transparent 96-well plates from 
Costar (part no. 3598) were used to perform the Bradford assay. For consistency, the standards 
were run in triplicate.  Each well contained 300 µL of the Coomassie Brilliant Blue G-250 dye 
along with the different concentrations of BSA standards.  The 96-well plate was ran using the 
EnVision® multlilabel reader, which was programmed to measure the absorbance at 595 nm 
with an 8 min delay.  The delay was programmed to 8 min in order to give the dye enough 
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time to bind with the proteins to give the dye enough time to bind with the proteins to produce 
the blue color.18 
 
Table 2.1.6 | Bradford Assay Standards.a  
 
a The table shows the amount of BSA used in order to create the standard curve. From this, a linear 
equation was obtained and used for the calculation of the Co-BsLuxS-HT protein concentration by 
solving for “x” using absorbance as “y”.18,19 
 
 
2.1.7 | Determination of Protein Concentration using NanoDrop Spectrophotometer ND-
1000.  The NanoDrop spectrophotometer is now the primary method to determine the 
concentration of the Co-BsLuxS-HT protein.  The LuxS sequence of the protein was inputted 
into the ProtParam program by ExPASy online.  The result given includes the molecular 
weight of the enzyme along its extinction coefficient (11460 M–1 cm–1), and the Co-BsLuxS-
HT absorbance at 1%, which is 6.23.  The absorbance at 0.1% was input into the NanoDrop 
spectrophotometer program, which was set to read at A280.  A blank was run using the elution 
buffer; only 2 µL of the buffer is needed. After the blank, 2 µL of the Co-BsLuxS-HT was 
BSA standard 
concentration 
(mg/mL) 
Volume of BSA standard 
(µL) 
Amount of BSA 
(µg) 
0 0 0 
0.125 4 0.5 
0.25 6 1 
0.25 4 1.5 
0.5 5 2 
0.5 4 2.5 
0.75 4.7 3 
0.75 4 3.5 
1 4 4 
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measured using the NanoDrop spectrophotometer.  The instrument was blanked three times 
and the Co-BsLuxS-HT was measured three times for consistency purposes. 
 
2.1.8 | SDS-PAGE.  After purification of the Co-BsLuxS-HT protein, an SDS-PAGE gel was 
run to assess the purity of the protein.  The pre-made 12.5% SDS-PAGE gel was set in the cell 
buffer dam, facing inwards.  Then, 1% running buffer was poured into the inner chamber until 
it overflowed the required level in the outer chamber.  The Co-BsLuxS-HT was mixed with 
loading dye containing the reducing reagent dithiothreitol (DTT) and was heated in boiling 
water for 10–15 min.  The gels were loaded with 2–4 µL of the dyed proteins and run at 150 V 
until the dye could be visually seen at the bottom of the glass plates.  The gels were removed 
from the glass plates and placed in a container that is rocked/shaken with dH2O to remove 
lingering running buffers (do 3X for 10 min each).  Approximately 20 mL of PageBlue Protein 
Staining Solution by Thermo Scientific was poured onto the SDS-PAGE gel and the container 
shaken overnight.  The next day, the gels were washed until the excess dye has been removed 
and the bands can be visually seen. 
 
 
2.2 | Computational Screening using DOCK Blaster.  Using DOCK Blaster, potential 
inhibitors of LuxS can be determined.  DOCK Blaster is freely available online and can be 
completely automated, which makes it applicable to anyone interested in computational 
screening.15–17 To use DOCK Blaster, a PDB code must be obtained from the Protein Data 
Bank website (http://www.rcsb.org/pdb/home/home.do).  Under the search bar, enter the 
molecule name “S-Ribosylhomocysteine” and click on “Bacillus subtilis”.  A list of all known 
LuxS structures from B. subtilis with SRH will be shown including their PDB codes.  The 
PDB codes chosen are 1JVI (closed ring SRH) or 1YCL (opened ring SRH).6,20 Next, the 
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DOCK Blaster site is opened (http://blaster.docking.org/).  Under the “Dock” tab, click on 
“Start with a PDB code”.   Enter PDB code 1JVI (closed-form SRH) and specify its 3-letter 
ligand code under “Ligand”, which is RHC (stands for Ribosylhomocysteine), then click on 
“Dock!”.  DOCK Blaster will submit a job and give a 5-digit query number.  This job number 
will be the identification code for the particular structure that was docked. (This step can take 
up an hour or more before proceeding to the next step).  Once “Calibration Docking” is 
complete, a score will be given.  Calibration docking represents the results of re-docked ligand 
in a table.  Green indicates good, yellow marginal, and red poor re-docking results.  There are 
two different sampling schemes (“Coarser” or “Finer”), which are used to sample ligand 
orientations.  There are also two different scoring schemes (“Amber” or “Polarized”), which 
use the partial atomic charges on a protein (“amber 94”) or increase the dipoles on selected 
polar atoms in residues within 3.5 Å (“polarized”) of the crystallographic ligand without 
changing the net charge.15 Pockets of different sites will also be given and can be chosen as the 
site in which to dock potential inhibitors; however, the site which SRH binds to the LuxS is 
automatically chosen without the need to manually pick a pocket.15,21 Since the goal of the 
project is to discover potential new competitive inhibitors for LuxS, docking can proceed after 
calibration.  Docking begins by choosing the database type.  Choose “By Vendor” and then 
under “Database (#) number of molecules” the vendor “kegg” is chosen.  The KEGG database 
was chosen because it contains the closed-SRH form, which gives a positive control to the 
docking experiment.  Sampling and scoring schemes can be chosen by either choosing 
sampling to run “Faster” or “Slower”.  There are also two types of scoring to choose from, the 
first one is “Scoring #1” or “Scoring #2”.  Once the selections for the schemes have been 
chosen, click on “Dock”.  Depending on whether the sampling scheme is fast or slow, the run 
can take a day or a few weeks for the results to be given.  Once the results are given, it can be 
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viewed under “subset kegg”.  Click on “subset kegg”; this page will show the results for every 
possible inhibitor from the KEGG database that supposedly binds to the LuxS active site.22 
The substrates are ranked based on how well they scored.  The more negative their score, the 
better the molecule is predicted to bind to the LuxS enzyme active site.15,17 The substrate S-D-
ribosyl-L-homocysteine (SRH) should have also re-docked as well (positive control).  After 
docking is complete, a new dock can then be initiated. (You may only dock one database at a 
time). By clicking on the PyMOL tab on each of the possible inhibitors, each inhibitor can be 
viewed using PyMOL, which is a program that produces high quality 3D images of small 
molecules to large macromolecules such as proteins.23 From PyMOL, it can be seen as to 
whether the potential inhibitor is indeed bound the LuxS active site in silico.15   
 
 
 
2.3 | Ellman’s Activity Assay.  The Ellman’s Activity assay is a colorimetric kinetics assay 
that measures the absorbance of a solution at 412 nm to indicate the presence of thiols.  The 
general procedural requirements for using Ellman’s assay to determine LuxS activity (in the 
absence of inhibitors) is derived from literature reports as described below.5,10 
 
 
2.3.1 | Chemical Reagents.  Ellman’s reagent (5,5'-dithiobis-(2-nitrobenzoic acid) or DTNB), 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) sodium salt, and NaCl were 
purchased from commercial sources. SRH was prepared synthetically in our laboratory. 
 
 
2.3.2 | Preparation of Ellman’s Activity Assay Reagents.  The methodology for the 
preparation of Ellman’s assay reagents is as follows: (a) 5× Co-BsLuxS-HT Buffer (250 mL).  
32.5 g of HEPES sodium salt (500 mM) was added into 250 mL of distilled water.  The pH 
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was then adjusted to 7 with concentrated HCl.  After pH has reached 7, 10.958 g of NaCl (750 
mM) was added to the buffer solution.  (b) Co-BSLuxS-HT (160 µM final working solution 
concentration – 150 µL working solution).  The determined concentration of Co-BsLuxS-HT 
from the NanoDrop spectrophotometer was 321.1 µM.  From the 321.1 µM stock of Co-
BsLuxS-HT, a 160 µM working solution was made with a final volume of 150 µL.  Add 30 
µL of 5× Co-BsLuxS-HT buffer, 74.7 µL of 321.1 µM Co-BsLuxS-HT, and 45.3 µL of 
distilled water together in a 1.5 mL Eppendorf tube to obtain a final working stock 
concentration of 160 µM of Co-BsLuxS-HT.  (c) S-Ribosylhomocysteine (SRH) (680 µM 
final working solution concentration – 1000 µL). 200 µL of 5× Co-BsLuxS-HT buffer, 34 µL 
of SRH (20 mM SRH stock) and 766 µL of distilled water were mixed together into a 1.5 mL 
Eppendorf tube.  (d) Ellman’s Reagent (DTNB) was prepared with a final working 
concentration of 15 mM with a final volume of 2 mL.  It was prepared by adding 0.01189 g of 
DTNB into 2 mL of 5× Co-BsLuxS-HT buffer.5,10   
 
  
 
2.3.3 | Ellman’s Activity Assay of Co-BsLuxS-HT.  All working solutions are kept 
separately until each assay run.  Table 2.3.3 below shows the amount of reagents needed for 
each run.  Directly into the 1 mL glass cuvette, add 200 µL of 5× Co-BsLuxS-HT buffer first.  
Then, add the appropriate amount of distilled water as listed on Table 2.3.3 and following after 
that, the appropriate amount of SRH is added (each assay run will having increasing amounts 
of SRH (0–68 µM final concentration in a cuvette)) in the cuvette.  The 5 µL of Co-BsLuxS-
HT is added to one side of the cuvette, making sure it is not immersed in solution yet, then add 
10 µL of DTNB to the other side of the glass cuvette.  Flip the glass cuvette over once with the 
cap that is provided with the cuvette and insert the cuvette into the Hewlett Packard B452A 
Diode Array Spectrophotometer quickly.  The spectrophotometer is programed to read at 412 
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nm and record its readings every 17 seconds for a total of 204 seconds.5,12 Make sure to let the 
diode array warm up its lamps before use for about 15–30 min before performing any run.  
Also, a blank run using the first mixture on Table 2.3.3 is required before continuing to run the 
Ellman’s Activity assay. 
 
 
Table 2.3.3 | Ellman’s Activity Assay.a  
 
[Final 
Concentration of 
SRH] (µM) 
5× LuxS 
Buffer (µL) 
dH2O 
(µL) 
680 µM SRH 
working 
solution (µL) 
160 µM LuxS 
working 
solution (µL) 
15 mM 
Ellman’s 
Reagents 
(DTNB) (µL) 
Blank 200 790 - - 10 
LuxS only 200 785 - 5 10 
SRH only 200 690 100 - 10 
1.060 200 783.4 1.56 5 10 
2.125 200 781.9 3.13 5 10 
4.250 200 778.8 6.25 5 10 
8.500 200 772.5 12.5 5 10 
17.000 200 760 25 5 10 
34.000 200 735 50 5 10 
68.000 200 685 100 5 10 
a The first three runs in the Ellman’s assay are controls.  After the blank, LuxS only, and SRH only runs 
have been conducted, increasing concentrations of SRH are tested to determine the activity of the Co-
BsLuxS-HT enzyme.  The concentrations that are listed in the first column are the final concentrations 
of SRH in the 1 mL cuvette when the assay is performed.  For each assay run, the initial rate of each run 
is recorded.  The initial rates are then calculated to give the specific units µmol/mg/min.7 They are then 
plotted using GraphPad Prism 5.0 in order to obtain the KM, Vmax, kcat, and kcat/KM values.  
 
 
2.3.4 | Kinetic Parameters Determination.  The calculated specific activity was plotted onto 
GraphPad Prism 5.0.  The specific activity was calculated using the extinction coefficient for 
DTNB (ε = 14,000 M–1 cm–1), protein amount (mg), pathlength (1 cm), time (min.), and initial 
rates of the increasing concentration of SRH.  A sample calculation can be seen below using a 
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sample initial rate of 2.20237 × 10–4.  Note that when the actual specific activity is plotted 
onto GraphPad Prism 5.0, the specific activity is plotted as 10–3 in order for easy comparability 
to the reports of Pei et al.5,7  
 
2.2!×!10!! !!"! ! !"# ∙ !"14000!! 1!" 60!!!"# ! 10!!!"#$! ∙ !"# ! 1!!1000! " ! ! 1! "0.059! "  
= 0. 016 µmol/mg/min 
A sample kinetics graph and its values can be seen on Figure 3.2.3.  
 
 
 
2.4 | LuxS Inhibition Assay.  The LuxS Inhibition assay is essentially the Ellman’s Activity 
assay except with the addition of increasing amount of inhibitor holding the amount of SRH 
constant.  Similar to the Ellman’s Activity assay, the LuxS Inhibition assay is a colorimetric 
kinetics assay that measures the absorbance of a solution at 412 nm.  Its general procedural 
requirements, as derived from literature reports,7,10 are described below:  
 
 
2.4.1 | Chemical Reagents.  Ellman’s reagent (5,5'-dithiobis-(2-nitrobenzoic acid or DTNB), 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) sodium salt, and NaCl were 
purchased from commercial vendors. SRH was prepared synthetically in our laboratory. 10 
 
 
2.4.2 | Preparation of LuxS Inhibition Assay Reagents.  The LuxS Inhibition assay reagents 
are prepared as follows: (a) 5× Co-BsLuxS-HT Buffer (250 mL).  32.5 g of HEPES sodium 
salt (500 mM) was added into 250 mL of distilled water.  The pH was then adjusted to 7 with 
concentrated HCl.  After the pH had reached 7, 10.958 g of NaCl (750 mM) were added to the 
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buffer solution.  (b) Co-BSLuxS-HT (160 µM final working solution concentration – 150 µL 
working solution).  The determined concentration of Co-BsLuxS-HT from the NanoDrop 
spectrophotometer was 321.1 µM.  From the 321.1 µM stock of Co-BsLuxS-HT, a 160 µM 
working solution was made with a final volume of 150 µL by adding 30 µL of 5× Co-
BsLuxS-HT buffer, 74.7 µL of 321.1 µM Co-BsLuxS-HT, and 45.3 µL of distilled water 
together in a 1.5 mL Eppendorf tube.  (c) S-Ribosylhomocysteine (SRH) (680 µM final 
working solution concentration – 1000 µL).  Mix together 200 µL of 5× Co-BsLuxS-HT 
buffer, 34 µL of SRH (20 mM SRH stock), and 766 µL of distilled water into a 1.5 mL 
Eppendorf tube.  (d) Ellman’s Reagent (DTNB) was prepared with a final working 
concentration of 15 mM with a final volume of 2 mL by adding 0.01189 g of DTNB into 2 mL 
of 5× Co-BsLuxS-HT buffer.5,7 (f) Inhibitors (Final working solution concentration 680 µM – 
2000 µL).  Inhibitors are initially prepared with a final concentration of 0.5 M.  From the 0.5 
M inhibitor stock, the 680 µM working solution was prepared by adding together 400 µL of 
5× Co-BsLuxS-HT buffer, 1597.3 µL of distilled water, and 2.72 µL of 0.5 M inhibitor.1–3,20,24   
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Table 2.4.2 | Ellman’s Inhibition Assay.a  
a The first four runs in the inhibition assay are controls.  After the blank, LuxS only, SRH only, and 
LuxS + SRH runs have been conducted, increasing concentrations of inhibitor are tested to determine 
the inhibition of the Co-BsLuxS-HT enzyme.  The inhibitor concentrations are listed in the first column 
with a final volume of 1 mL in the cuvette when the assay is performed.  For each assay run, the initial 
rate of each run is recorded.  The initial rates are calculated to give the specific units µmol/mg/min.7 
They are then plotted the same way as the Ellman’s assay using GraphPad Prism 5.0 in order to obtain 
the KM, Vmax, kcat, and kcat/KM values. 
 
2.4.3 | IC50 Determination for Selected Inhibitors.  The IC50 values were determined for 
substrates that showed initial promise in inhibition of the LuxS enzyme from the Ellman’s 
Inhibition Assay (Section 2.4.2).  It was imperative that the IC50 was determined so that it can 
Final 
Concentration 
of SRH] (µM) 
5× LuxS 
Buffer (µL) 
dH2O (µL) 
680 µM 
SRH 
working 
solution 
(µL) 
160 µM 
LuxS 
working 
solution 
(µL) 
680 µM 
Inhibitor 
(µL) 
15 mM 
Ellman’s 
Reagents 
(DTNB) 
(µL) 
Blank 200 790 - - - 10 
LuxS [34 µM] 
only 200 780 - 10 - 10 
SRH [68 µM] 
only 200 690 100 - - 10 
LuxS [34 µM]  
+ SRH [68 
µM] 
200 680 100 10 - 10 
LSI [68 µM] 200 580 100 10 100 10 
LSI [136 µM] 200 480 100 10 200 10 
LSI [204 µM] 200 380 100 10 300 10 
LSI [272 µM] 200 280 100 10 400 10 
LSI [340 µM] 200 180 100 10 500 10 
! 24 
be seen how much of the potential inhibitor is needed to inhibit the LuxS enzyme by fifty 
percent.  This was accomplished by using the initial rate of each assay to calculate the percent 
activity of the enzyme as increasing amounts of potential inhibitor is added to the Ellman’s 
assay.  The IC50 values of Argininosuccinate and L-NAME were calculated and determined.  
Equation for the calculation of the IC50 is shown below. 
 
%!!"ℎ!"!#!$%! = !"#$%&!!"#$%$#&! − !"ℎ!"!#$%!!"#$%$#&!"#$%&!!"#$%$#& ×!100% 100! − !%!!"ℎ!"!#!$% = !%!!"#$%$#& 
Table 2.4.3 | Determination of IC50 Values.a   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
Process of how the % Activity was determined and eventually was graphed with the y-axis as % 
Activity and the x-axis is the log of inhibitor concentrations 68 µM, 136 µM, 204 µM, 272 µM, and 
340 µM.!
Sample I.D. 
Corrected 
LuxS 
Absorbance 
(A280) 
% Inhibition % Activity 
LuxS [1.6 µM] + 
SRH [34 µM] 
 
36 
 
0 
 
100 
 
LSI [68 µM] 30 –0.17 83 
LSI [136 µM] 22 –0.38 62 
LSI [204 µM] 20 –0.45 55 
LSI [272 µM] 11 –0.70 30 
LSI [340 µM] –2.1 –1.1 –5.8 
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Chapter 3: Spectrophotometry 
!
3.1 | Spectrophotometers.  Spectrophotometry is widely used in biochemical analysis to 
calculate the concentration of a substance in solution.  Spectrophotometry is defined as the 
measurement of color within a solution by observing the quantity of light being absorbed 
using a spectrum of ultraviolet, infrared, or visible light.14,25,26 A wavelength (λ) is defined as 
the distance between adjacent peaks in a wave.14.26 Each compound has a different 
characteristic wavelength of light that it absorbs.  For example, when a solution appears 
green, it is because the blue and yellow light is being transmitted and the red light is being 
absorbed by the compound in solution.  The relationship that connects the absorption of light 
to the concentration of the absorbing solution is determined using the Beer–Lambert Law.  
The Beer–Lambert Law equation is defined as: Α = !!!×!!!×!! 
where A is absorbance and has no unit.  Epsilon (ε) is the extinction coefficient and has the 
units M–1 cm–1.  The pathlength (l) is in units of cm and is usually assumed to be 1 cm unless 
otherwise suggested.14,25,26 The concentration (c) has a unit that is the reciprocal of the epsilon 
unit.25,26 This equation is typically used to determine the concentration of a compound in 
solution. In cases where the extinction coefficient ε is unknown, a standard curve 
methodology may be used.   
 
In biochemistry, spectrophotometry is a useful technique for both determining the 
concentration of proteins and small molecules in solution and also for studying enzyme 
kinetic activity using the Michaelis–Menten equation.  Here, spectrophotometry allows for 
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the determination of the enzyme activity by relating the reaction rate (V) of the enzyme 
obtained from the spectrophotometer to the substrate [S] concentration in the presence of an 
enzyme of interest.26 
!!! = !!!"# ! [!]! + !!! 
The Michaelis–Menten constants KM, kcat, and Vmax can be automatically determined using 
graphing programs such as GraphPad Prism when the specific activity of the enzyme is 
graphed against the substrate concentration. 
 
 
3.1.1 | PerkinElmer EnVision 2104 Multilabel Reader.  The EnVision Multilabel Plate 
Reader instrument was initially used in this project to perform the Bradford assays in order to 
determine protein concentration.18 Here, the EnVision is programmed to read absorbance at 
595 nm using the 96-well plate.  Using the 96-well plate allows for triplicate readings in just 
a single run and in less than 20 seconds.  
 
 
 
 
 
 
 
 
 
Figure 3.1.1 | EnVision Plate Reader.  Image of the PerkinElmer Envision 2104 Multilabel Plate 
Reader and 96-well plate that is used to perform Bradford assays. 
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3.1.2 | NanoDrop Spectrophotometer.  The NanoDrop spectrophotometer is another type of 
spectrophotometer instrument that measures the absorbance of light by a compound of 
interest.  The NanoDrop spectrophotometer is usually used to determine the concentration of 
DNA.  However, it can also be used to accurately determine protein concentration using the 
“other protein (E1%)” option.27 For proteins of known primary sequence that are purified, 
concentration can be quantified by reading absorbance at 280 nm.  The result is given in 
mg/mL and the concentration of the protein can be accurately determined up to 100 mg/mL 
without dilution. The NanoDrop spectrophotometer is best used to test samples of volumes as 
little as 1 µL, however, when dealing with proteins, 2 µL of volume is recommended in order 
for accurate reading of the protein concentration.27 
 
 
 
 
 
 
 
 
Figure 3.1.2 | NanoDrop Spectrophotometer.  A picture of the NanoDrop Spectrophotometer ND-
1000 and P-2 pipetman that is used for protein concentration determination. 
 
 
 
3.1.3 | Agilent 8453 UV–Vis Spectrophotometer.  The Agilent 8453 UV–Vis 
spectrophotometer uses diode array technology.  The photodiode array contains 1024 
individual photodiodes and the control circuits are within the semiconductor chip.  The 
Agilent 8453 UV–Vis has a wavelength range between 190 nm and 1100 nm. The UV–Vis 
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spectrophotometer can be used to read at a fixed wavelength or multiple wavelengths.  It can 
also be used to run biochemical analyses such as running a kinetics assay.  The UV–Vis can 
run a kinetics assay by programming the program to run time-dependently and to be able to 
take measurements at specific time intervals in the assay. 
  www.medicinescomplete.com 
 
Figure 3.1.3 | UV–Vis Spectrophotometer. (Left) Image of Agilent 8453 UV–Vis spectrophotometer.  
(Right) Diagram of typical UV–Vis spectrophotometer anatomy that shows how the light source hits 
the cuvette containing the sample.14,25,26  
 
 
3.2 | Spectrophotometric Assays. UV–Vis spectrophotometry may be used to study enzymes 
by determining protein concentrations and the concentrations of other analytes in solution 
such as the products of an enzymatic reaction. Depending on the type of cuvette that is being 
used, a total volume of 1 mL is usually needed in order for instruments such as the Agilent 
UV–Vis spectrophotometer to be able to read absorbances.  However, for instruments such as 
the EnVision Multilabel Plate Reader by PerkinElmer, only 600 µL of volume is needed for 
each well in a 96-plate well.  For the NanoDrop spectrophotometer instrument, 2 µL of 
volume is all that is needed to read the concentration of the solution. 
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3.2.1 | Bradford Assay.  The Bradford assay is a type of biochemical analysis used to 
determine the concentration of a protein in solution, which was developed by Marion M. 
Bradford.  It is a colorimetric assay in which the absorbance is being measured at 595 nm.  
The protein solution turns more intensely blue as proteins bind to the Coomassie Brilliant 
Blue G-250 dye. In acidic conditions, the proteins will bind to the Coomassie Brilliant Blue 
G-250 dye, which then turns the dye blue.  The original red color is due in part to the dye 
being acidic and doubly protonated in a cation form.  When the protein is bound the solution 
turns blue, which is stable and unprotonated.  The blue color is the result of basic amino acids 
such as histidine, lysine, and mainly arginine binding to the dye.18,19 The binding of proteins 
to the dye is caused by van der Waals forces and hydrophobic interactions. Hydrophobic 
interaction is defined as the interaction between non-polar hydrocarbons that are forced to 
bind to each other by the surrounding water interactions.14 These are prevalent within the 
Bradford assay because the protein that binds to the Coomassie Brilliant Blue G-250 dye has 
a native tertiary structure that is disrupted by the donation of a free electron by the Coomassie 
Brilliant Blue G-250 to an ionizable group within the protein, which reveals the hydrophobic 
pockets within the enzyme.18,19 Van der Waals interaction is defined as a weak force 
attraction between non-polar molecules that is caused by a change in dipole moment.  Van 
der Waals interactions are much weaker than chemical bonds.14 In regards to the Bradford 
assay, van der Waals forces influences the binding of the hydrophobic pockets of the enzyme 
to the Coomassie Brilliant Blue G-250 dyes’ non-polar region by non-covalent binding.  In 
order to determine the concentration of a protein by the Bradford method, a standard curve is 
first created using increasing known concentrations of the commodity protein BSA. The 
absorbance of a solution of the protein of interest is evaluated against the equation of the 
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standard curve line. The sample solution may require dilution in order to fit into the standard 
curve. 
 
 
 
3.2.2. NanoDrop Spectrophotometer. The concentration of a purified enzyme can presently 
be determined more directly using the NanoDrop spectrophotometer ND-1000.  From the 
NanoDrop spectrophotometer menu, “Protein A280” was chosen.  Once the screen opens, 
“other protein (E1%)” is where the absorbance at 1% is input.   To obtain absorbance 1% 
from the sequence of the protein of interest using the free online program ExPASy, on the 
ExPASy website (www.expasy.org), the “ProtParam” button was selected and the sequence 
of the enzyme can then be input.  The result was obtained by clicking “Compute parameters”.  
The result from the computed parameters includes the molecular weight, amino acid 
composition, atomic composition, extinction coefficient, and the estimated half-life of the 
enzyme of interest.27 
 
 
 
3.2.3 | Ellman’s Activity Assay.  The Ellman’s Activity Assay is performed using the 
Agilent 8453 UV–Vis Spectrophotometer.  A typical Ellman’s assay contains of 5× LuxS 
Buffer, dH2O, increasing concentrations of SRH, 1.6 µM Co-BsLuxS-HT, and 150 µM of 
DTNB (Ellman’s Reagent).  The contents are added into a quartz cuvette with a final volume 
of 1 mL.  The UV–Vis spectrophotometer is set to measure the protein activity at 412 nm for 
a total of 204 seconds every 17 seconds.3,5,7 The initial rate of each run from the increasing 
concentration of SRH is taken and graphed using GraphPad Prism.  The concentrations of 
SRH substrate used to help determine the activity of the Co-BsLuxS-HT are 0.000 µM, 1.060 
µM, 2.125 µM, 4.250 µM, 8.500 µM, 17.000 µM, 34.000 µM, and 68.000 µM. As the 
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concentration of SRH substrate is increased, it can be seen visually at the end of the kinetic 
assay that the solution contents turn more yellow, which is the product from the Ellman’s 
reagent.  The Ellman’s assay of the Co-BsLuxS-HT reaction can be described by the initial 
binding reaction of the substrate (SRH) to the enzyme Co-BsLuxS-HT, which produces 
homocysteine and DPD at a 1:1 ratio.  The homocysteine reacts with the Ellman’s reagent 
(DTNB) to form the yellow product, 2-nitro-5-thiobenzoate, which is being measured at 412 
nm using the Agilent 8453 UV–Vis Spectrophotometer.3,5,20 The initial rates (AU/s) that are 
obtained from UV–Vis spectrophotometer are converted into specific activity 
(µmol/mg/min).7 The specific activity is input onto GraphPad Prism in the y-axis in 
correlation to the increasing concentration of SRH, which is input into the x-axis.  GraphPad 
Prism will automatically calculate the KM, Vmax, kcat, and Kcat/KM values from the graph. A 
sample graph from an initial assay of LuxS is included in Figure 3.2.3 for illustration. 
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A 
 
 
 
 
 
 
B 
KM (µM) 6.1 
Vmax (µmoles/min) 310 
kcat (min-1) 3.9 
kcat / KM (µM-1 min-1) 0.64 
 
Figure 3.2.3 | Michaelis-Menten Graph.  (A) Above is a Michaelis-Menten graph of Co-BsLuxS-HT, 
which shows the activity of the enzyme as the concentration of the substrate, S-ribosylhomocysteine 
(SRH), is increased.  (B) Kinetics results from Ellman’s assay of Co-BsLuxS-HT. 
 
The Michaelis constant KM describes the amount of substrate concentration needed for 
enzyme reaction to occur at half-maximal velocity.  Therefore, if the KM value is high, a 
higher concentration of substrate is needed for catalysis to proceed, which means that the 
substrate has low affinity for the enzyme and vice versa.28 Vmax is the maximal velocity in 
which the enzyme catalyzes the reaction.  kcat is often considered as the “turnover number”, 
which measures the catalytic production of products.  Finally, kcat/KM measures the catalytic 
efficiency of the enzyme reaction.  The greater the kcat/KM value is, the faster the substrate is 
converted into products.28 
 
Increasing Concentration of SRH vs. Specific Activity using 160uM of ELS1409 at 1.17mM (7.26.12)
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3.3 | Application of Spectrophotometric Techniques to the Study of LuxS.  With the use 
of the different types of spectrophotometers mentioned above, the LuxS enzyme 
concentration can first be quantified after purification, and then the activity of the LuxS 
enzyme determined.  Using the NanoDrop spectrophotometer as well as performing the 
Bradford assay on a plate reader such as the PerkinElmer EnVision, the LuxS concentration 
can be determined and compared accordingly.  Furthermore, once potential inhibitors are 
targeted, the UV–Vis diode array spectrophotometer can be used to test whether inhibition is 
occurring by performing an activity assay such as the Ellman’s assay. 
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Chapter 4: Purification of LuxS and Optimization of Activity Assay 
 
4.1 | LuxS Purification.  The purification of an enzyme is an important process in 
biochemistry, through which impurities are removed so that the desired protein can be 
isolated and obtained.  There are several different options for purifying a protein, such as 
separation by size, affinity, or physical/chemical properties.  Thus, before the purification of 
LuxS can occur, it is important to know that background of the Co-BsLuxS-HT.  Co-BsLuxS-
HT was inserted into the pET-22b(+) vector, which has six histidines attached on the C-
terminus end of the DNA sequence and has a ampicillin resistance marker.  Once the DNA is 
inserted into the vector by cloning, the DNA vector can be transformed into an expression 
cell-line.  The expression cell-line used is BL21[DE3] Gold, which is used to express the 
LuxS protein sequence.10,11 Based on previous studies done for the protein purification of Co-
BsLuxS-HT enzyme, the enzyme was isolated using an affinity column.  The affinity column 
of choice used in purifying the Co-BsLuxS-HT enzyme is a cobalt column.7 
 
 
 
4.1.1 | LuxS Overexpression and Cell Harvesting.  In order to isolate the Co-BsLuxS-HT 
protein, the purification of Co-BsLuxS-HT begins by overexpressing the cells for three days, 
which allows for the minimization and control of potential contamination.  The procedure 
used mirrors that reported in the literature.7 Cells are grown by initially inoculating a 5 mL 
LB starter culture containing ampicillin75 with the Co-BsLuxS-HT stock and incubating it for 
16 h overnight at 37 oC. The cell line in which the LuxS sequence was inserted in contains an 
ampicillin resistance sequence that allows only those cells resistant to this antibiotic to grow 
in culture.  The next day, a 1:1000 back-dilution was performed by adding 50 µL of the 
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starter culture into 50 mL of LuxS minimal media containing ampicillin75 and shaking it for 
16 h in the incubator at 37 oC.  The following day, a 1:50 back-dilution was done by adding 
10 mL of the 1:1000 back-dilution culture into 500 mL of LuxS minimal media containing 
ampicillin75 (2 L total).  The 2 L cultures were shaken in the 37 oC incubator for 2 h with its 
OD600 was measured every 30 min. The desired optical density of bacteria to be obtained is at 
0.6, this is because 0.6 is where the exponential growth of bacteria lies (cell-doubling).29 
Once the optical density has reached ~ 0.6, the cultures were removed from the shaker to 
decrease the temperature of the shaker to 30 oC and adding 200 µM of cobalt chloride.  
Additional cobalt chloride was added to ensure that the LuxS proteins are enriched with 
cobalt as its metal cofactor so that when eluted, the proteins are purple.  The cultures were 
then put back into the shaker for an additional 30 min before inducing with 100 µM IPTG for 
16 h overnight at 30 oC.  Induction occurs using IPTG because it is part of the pET expression 
system control in which IPTG acts as the analog of the lac repressor in cell line.  The lac 
genes are responsible for the expression of proteins involved in the breakdown of lactose or 
in this case IPTG, which because of its presence initiates transcription of the lac genes. The 
cells were harvested the next day by centrifuging the cells down at 5,000 rpm for 20 min.  
The cells were collected and stored at –80 oC until the cells are ready to be lysed.10,29 
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Table 4.1.2 | Representative OD600 values for LuxS overexpression cultures. 
 
 
4.1.2 | Cell Lysis.  There are many different methods used to lyse bacterial cells such as by 
sonication, French press, or microfluidizers.  The reason for wanting to lyse a bacterial cell is 
to release its fluid contents, also known as its lysate.  The lysate contains the desired enzyme; 
in this case, the desired enzyme is Co-BsLuxS-HT.  After the cell has been lysed and spun 
down again, protein purification can then be performed.30 While the literature reports a 
sonication-based method for the lysis of E. coli BL21[DE3] cells, previous work from our 
laboratory suggested that alternate means of cell lysis were appropriate given the equipment 
available.32 
 
 
 
4.1.2.1 | French Press.  The instrument of choice for the lysis of the bacterial cells containing 
the Co-BsLuxS-HT enzyme is the French Press.  The French Press uses pressure to disrupt 
cells.  The French Press uses a manual pump to create pressure that pushes a piston within a 
cylinder that contains a suspension of cells, which is then forced through a needle valve.  The 
pressure generated by the force is then able to disrupt the cell membranes, allowing the lysate 
to be released.  Preparation of the Co-BsLuxS-HT to be lysed includes suspending the cells 
Absorbance Time 
(started after 2 h of 
shaking) 
OD600 
(Flask 1) 
OD600 
(Flask 2) 
OD600 
(Flask 3) 
OD600 
(Flask 4) 
12:40 0.17 0.21 0.19 0.15 
1:10 0.26 0.30 0.28 0.24 
1:40 0.35 0.30 0.38 0.34 
2:10 0.47 0.56 0.51 0.44 
2:40 0.64 0.74 0.69 0.60 
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into 35 mL lysis buffer, which is then added into the French Press cylinder.  The piston is 
then inserted at the top for the French Press to begin. The cells were then lysed at 20,000 psi 
and the collected lysate was spun down at 5,000 rpm using the centrifuge for 20 min at 4 oC. 
 
 
 
 
 
 
 
 
 
 
Figure 4.1.2.1 | French Press.  Image of the French pressure cell used to obtain the Co-BsLuxS-HT 
lysate. 
 
 
4.1.3 | Affinity Chromatography.  Affinity chromatography is a purification method used to 
separate mixtures given highly specific interactions between analyte and the stationary phase 
of the chromatography column.  In the case of the enzyme Co-BsLuxS-HT, six histidines are 
artificially included in its sequence.  This “His-tag” has an affinity for metal ions, particularly 
nickel and cobalt.  This affinity allows for Co-BsLuxS-HT to bind onto a cobalt affinity 
column and elute out only with excess amounts of the metal ion ligand, imidazole. 
 
 
4.1.3.1 | Hand Column.  Originally, the purification of the Co-BsLuxS-HT enzyme was done 
using a hand column.  The hand column uses gravity to push out the buffers and protein from 
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the column.  Purification proceeds by adding 5 mL of TALON cobalt resin to the hand 
column; the Co-BsLuxS-HT enzyme was then purified by equilibrating the column with 3 
column volumes of lysis buffer before adding the centrifuged lysate.  The column was then 
washed with 35 mL of wash buffer, loaded with lysate, and eluted out in ~ 1 mL aliquots with 
40 mL of elution buffer.  Fractions containing LuxS were visually identified (purple 
coloration) and collected into a single sample for further analysis. 
 
 
 
4.1.3.2 | ÄKTAprime Plus.  The ÄKTAprime plus is an instrument that performs automated 
protein purification using pre-packed chromatography columns.  For the purification of Co-
BsLuxS-HT, the 5 mL HiTrap TALON crude was used to purify the proteins.  The pre-
packed column was attached to the ÄKTA and a pre-programmed protocol was chosen to run 
the purification process.  The program chosen was “Affinity Purification any HiTrap”.  The 
purification proceeds almost the same way as the hand column, except that the program can 
control the flow-rate and pressure. Fractions containing LuxS were identified by the UV trace 
generated by the ÄKTA system. The concentration of protein in each individual fraction was 
determined by spectrophotometry (i.e., NanoDrop, see section 4.2.2) before combining.10  
 
 
 
4.2 | Determination of Co-BsLuxS-HT Enzyme Concentration.  It is imperative to have an 
accurate protein concentration when running any enzyme experiment, especially kinetic 
assays.  Having a precise protein concentration allows for accurate comparability to published 
data.  There are two possible spectrophotometric methods of finding the protein concentration 
of purified Co-BsLuxS-HT.  The first is by a colorimetric assay called a Bradford assay and 
the second method is by using a NanoDrop spectrophotometer. 
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4.2.1 | Bradford Assay.  Initially, the concentration of Co-BsLuxS-HT was determined by 
performing a Bradford assay.  The Bradford assay is a colorimetric assay that is used to 
determine the protein concentration by the absorbance shift of the Coomassie Brilliant Blue 
G-250 dye (see Section 3.2.1). Here, the Bradford assay was performed using the EnVision 
spectrophotometer using 96-well plates.  A standard curve was first created from a set of 
known BSA concentrations (Figure 4.2.1A).  From this, it could then be determined what the 
unknown concentration of the Co-BsLuxS-HT protein is from the linear regression equation 
from the BSA standard set. In order to achieve an absorbance reading for LuxS that fell 
within the linear range of the standard curve, dilutions of 1:10, 1:20, 1:40, 1:80, and 1:160 
were made to the collected LuxS fractions. The absorbance of the 1:80 dilution fell within the 
range of the standard curve graph and therefore was chosen as the concentration for the Co-
BsLuxS-HT enzyme (Figure 4.2.1B). 
A  
 
 
 
 
 
 
 
 
 
 
 
y!=!0.076×!+!0.014!R2!=!0.98!
!40 
B        
LuxS Dilutions Corrected Abs. Concentration in mM 
1:10 ELS1409 1.1 0.96 
1:20 ELS1409 0.99 1.8 
1:40 ELS1409 0.61 2.1 
1:80 ELS1409 0.34 2.3 
1:160 ELS1409 0.20 2.7 
 
C 
Absorbance: 0.34 Volume: 4 µL 
Total Volume: 1400 µL Factor: 80 
 
Equation: y = 0.076× + 0.014 
Calculation: 
(0.34 - 0.014) / 0.076 = 4.3 µg (amount of protein) 
4.3 µg / 4 µL = 1.1 µg / µL 
1.1 µg / µL ×80 = 85 µg / µL  
(85 µg / µL ÷1000000) / 37000) ×1000000000 = 2.3 mM 
Figure 4.2.1 | Bradford Assay.  (A) Standard curve of Bradford assay using BSA standards.  The 
standard curve was created in order to obtain the linear regression equation, which can be used to 
calculate the protein concentration of Co-BsLuxS-HT.  (B) Dilutions of the Co-BsLuxS-HT was made 
in order to fit the standard curve, so that the protein concentration may be determined accurately.  The 
absorbance of the dilution must fall within the standard curve and then the concentration can be 
calculated by solving for x.  (C) Calculation of LuxS concentration from Bradford Assay. 
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4.2.2 | NanoDrop.  The second method used to determine the concentration of Co-BsLuxS-
HT is by using the NanoDrop spectrophotometer.  The NanoDrop spectrophotometer method 
was introduced because of concentration discrepencies that arose in the Bradford assay.  
Using the NanoDrop, the concentration of Co-BsLuxS-HT can be directly determined with 
the use of its extinction coefficient (11,460 M–1 cm–1) and the Co-BsLuxS-HT absorbance at 
1%, which is 6.23, which were both aquired using the ProtParam tool from ExPASy by 
simply inputing the protein sequence of Co-BsLuxS-HT.10  The NanoDrop requires only 2 µL 
of solution for the reading to proceed at absorbance of 280 nm.  The conclusion to use the 
NanoDrop concentration over the Bradford assay was finalized by the similarity in data it 
obtained when running the Ellman’s assay in comparison to literature reports.7 
 
 
Table 4.2.2 | NanoDrop Concentration Data.   
 
NanoDrop Concentration 
(mg/mL) 
Calculated Concentration 
(mM) 
6.2 1.2 
 
 
 
 
4.3 | Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE).  SDS-
PAGE is a popular technique used in biochemistry and in other similar disciplines.  The 
sodium dodecyl sulfate (SDS) is a detergent used to denature proteins so that all of the 
protein structure are linearized to the same shape and altered in the overall charge to be 
negative.  The gel used is a polyacrylamide gel, which allows for the separation of proteins 
by size.  When the gel is placed in an electric field, the proteins are then separated based on 
their size. The proteins travel by size towards the positive pole with smaller proteins 
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travelling faster than the larger proteins, which means that at the end of the run, the smaller 
proteins will be at the bottom of the gel.   
 
 
4.3.1 | SDS-PAGE to Determine LuxS Purity.  After the purificaiton of Co-BsLuxS-HT 
from the ÄKTAprime plus, an SDS-PAGE was run in order to check its purity.  A pure Co-
BsLuxS-HT protein will show a single band at ~18 kD on an SDS-PAGE gel.  As mentioned 
earlier, the purity of the enzyme Co-BsLuxS-HT is of great signifance to the success of 
running kinetic assays.  Therefore, before the Co-BsLuxS-HT enzyme is used in the Ellman’s 
assay or Inhibition assay, its purity must always be checked using the SDS-PAGE after its 
protein concentration has been determined either by Bradford assay or NanoDrop 
spectrophotometer. 
 
 
 
 
 
 
 
 
 
Figure 4.3.1 | SDS-PAGE.  SDS-PAGE of Co-BsLuxS-HT from its purification using ÄKTAprime 
plus.  The Co-BsLuxS-HT enzyme monomer is ~18 kD in size, which is confirmed by this SDS-PAGE 
analysis.  
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4.4 | Optimization of Ellman’s Assay for LuxS Activity.  The Ellman’s assay is used for 
the quantification of thiols in a sample. S-D-Ribosyl-L-homocysteine (SRH) is the substrate 
that is converted into DPD and homocysteine (a thiol) by the enzyme Co-BsLuxS-HT.  In the 
Ellman’s assay, the homocysteine is then converted into a disulfide conjugate with DTNB, 
which releases the compound 2-nitro-5-thiobenzoate. 2-Nitro-5-thiobenzoate is a yellow 
product that is monitored at 412 nm.  The conditions that are required for a typical Ellman’s 
assay are 1.6 µM Co-BsLuxS-HT enzyme, 5×  LuxS Buffer, DTNB, and increasing 
concentrations of SRH.7,10 Initially, the Ellman’s assay required troubleshooting because of 
the rapid conversion of the homocysteine into the 2-nitro-5-thiobenzoate (yellow product) 
that resulted in unacceptably high background.  Therefore, changes were made to the 
preparatory stages of the Ellman’s assay.  Previously, a combined mixture of the 5× LuxS 
Buffer and DTNB were prepared accordingly to the amount that will be used for each run.  
The SRH was diluted to each specific concentration that was to be tested, while adding the 
Co-BsLuxS-HT protein last was to initiate the reaction for the assay.  In protocol revision, it 
was decided that every component should be added individually for each assay run at each 
desired concentration.  The irregular activity shown in the previous methodology could be 
due to the fact that SRH was diluted well prior to the assay, which sat on ice for quite some 
time before usage.  The order that was best suited for the assay and gave the most optimal 
result in correlation to Pei et al.7 was to initially add the 5×  LuxS Buffer, desired 
concentration of SRH that was taken directly from stock (and not previously diluted), DTNB, 
and Co-BsLuxS-HT.  By following this specific order, the assay did not initiate until the Co-
BsLuxS-HT was added to the opposing side of the cuvette from the DTNB and mixed by 
turning the cuvette over twice before inserting it into the UV–Vis spectrophotometer for 
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reading.  (See Table 2.3.3 for the particular concentrations and volumes of each assay 
component used.) 
 
 
4.4.1 | Ellman’s Assay.  The Ellman’s Activity Assay is performed using the Agilent 8453 
UV–Vis Spectrophotometer.  A typical Ellman’s assay contains of 5× LuxS Buffer, dH2O, 
increasing concentrations of SRH, 1.6 µM Co-BsLuxS-HT, and 150 µM of DTNB (Ellman’s 
Reagent).  The contents are added into a quartz cuvette with a final volume of 1 mL.  The 
UV–Vis spectrophotometer is set to measure the protein activity at 412 nm for a total of 204 
seconds every 17 seconds.  The initial rate of each run from the increasing concentration of 
SRH is taken and graphed using GraphPad Prism.  The concentrations of SRH substrate used 
to help determine the activity of the Co-BsLuxS-HT are 0.000 µM, 1.060 µM, 2.125 µM, 
4.250 µM, 8.500 µM, 17.000 µM, 34.000 µM, and 68.000 µM.3,7,10 As the concentration of 
SRH substrate is increased, it can be seen visually at the end of the kinetic assay that the 
solution contents turn more yellow, which is the product from the Ellman’s reagent.  The 
Ellman’s assay of the Co-BsLuxS-HT reaction can be described by the initial binding 
reaction of the substrate (SRH) to the enzyme Co-BsLuxS-HT, which produces homocysteine 
and DPD at a 1:1 ratio.  The homocysteine reacts with the Ellman’s reagent (DTNB) to form 
the yellow product, 2-nitro-5-thiobenzoate, which is being measured at 412 nm using the 
Agilent 8453 UV–Vis Spectrophotometer.7 The initial rates (AU/s) that are obtained from 
UV–Vis spectrophotometer are converted into specific activity (µmol/mg/min).1,3,7,12 (See 
Appendix D for Calculation). The specific activity is inputted onto GraphPad Prism in the y-
axis in correlation to the increasing concentration of SRH, which is inputted into the x-axis.  
GraphPad Prism will automatically calculate the KM, Vmax, kcat, and kcat/Km values from the 
graph.  The Michaelis constant KM describes the amount of substrate concentration needed 
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for enzyme reaction to occur.  Therefore, if the KM value is high, a higher concentration of 
substrate is needed for catalysis to proceed, which means that the substrate has low affinity 
for the enzyme and vice versa. Vmax is the maximal velocity in which the enzyme catalyzes 
the reaction.  kcat is often considered as the “turnover number”, which measures the catalytic 
production of products. Finally, kcat/KM measures the catalytic efficiency of the enzyme 
reaction.  The greater the kcat/KM value is, the faster the substrate is converted into 
products.7,14,28 
 
 
 
4.4.2 | Kinetic Comparison.  The protein concentration results from the Bradford assay and 
NanoDrop spectrophotometer were compared by comparing the Ellman’s assay results of 
each because of the disparity between the kinetics data obtained from the Bradford 
concentration and the reported literature values. 7  The NanoDrop spectrophotometer was 
therefore used to solve this variation issue since its concentration values seem to match the 
kinetics data and graph of the literature values more than the values that were aquired from 
the Bradford assay.   
 
 
 
 
 
 
 
 
!46 
A (Nanodrop)        B (Bradford Assay)                                              
 
 
 
 
 
 
 
 
C  
Kinetic constants Kinetics Data from 
Bradford 
Concentration 
Kinetics  Data from 
NanoDrop 
Concentration 
Kinetics Data as 
reported in the 
literature7 
Vmax (µM/s) 63 32 Not provided 
KM (µM) 3.9 ± 0.94 2.1 ± 0.95 2.3  ± 0.5 
kcat (s-1) 0.79 ± 0.050 0.40 ± 0.040 0.04 ± 0.003 
 
Figure 4.4.2 | Kinetic Comparisons.  (A) Kinetic assay using the concentraion obtained from the 
nanodrop, which is 1.2 mM.  Assay is done by taking the intial rate of each assay run of increasing 
concentration of SRH and plotting it using GraphPad Prism.  (B)  Kinetic assay of Co-BsLuxS-HT 
with its concentration obtained from the Bradford assay, which was calculated to be 2.40 mM.  The 
graph was created by plotting the intial rates from each of the increasing concentrations of SRH onto 
GraphPad Prism.  (C)  Table of the kinetic values obtained from GraphPad Prism.  Although the data 
do not match the literature precisely, the concentration obtained from the NanoDrop gave enzyme 
activity closer to the one in the literature.7 
 
 
4.5 | Conclusion and Future Directions.  The Ellman’s Activity assay has been completely 
optimized with the use of the NanoDrop Spectrophotometer ND-1000 to obtain accurate 
protein concentration and optimized reagent preparation and order of addition.  By 
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implementing the Michaelis–Menten equation, the activity of the Co-BsLuxS-HT enzyme can 
be determined from the KM, Vmax, kcat, and kcat/KM values and compared to values reported in 
the literature.  For future directions, it would be advantageous to run the Ellman’s Activity 
assay using the PerkinElmer EnVision Multilabel Plate Reader so that multiple assays can be 
run at once and with significantly less material. 
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Chapter 5: Computational Screening for Potential Competitive 
Inhibitors of LuxS 
 
 
Computational screening, or virtual screening, is a method used for the discovery of bioactive 
small molecules such as substrates in drug discovery.  Screening can either be ligand-based or 
structure-based.  For ligand-based screening, a model receptor is determined for sets of 
known ligands or structurally similar ligands by testing how well the ligands bind to the 
model receptor, whereas structure-based screening is involved in scoring a library of ligands 
that can differ from one another and determining the affinity of each ligand to the known 
receptor.  Computational screening has been a key method for drug discovery within the 
science industry.16,23  Many companies use computational chemists to help look for substrates 
that would competitively inhibit their target.  Other times, substrates are designed to be part 
of a docking system as a potential substrate for an unknown target yet to be discovered. For 
this particular experiment, the purpose is to computationally screen for substrates using 
databases containing a variety of compounds that can potentially bind competitively to an 
enzyme active site (structure-based).  Through the database, each substrate is docked onto the 
target and scored on how well it binds.  Most computational screening methodologies require 
knowledge of Linux systems to focus on designing ligands for a specific target.  Recently, 
screening has been made more accessible to the general scientific community since programs 
such as DOCK Blaster have made it user-friendly because screening can be completely 
automated.15  
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Figure 5 | DOCK Blaster Computational Screening Method.  Overview of how computational 
screening programs such as DOCK Blaster perform.  Target and substrates are docked together onto a 
computational program and scored based on binding specificity.  Higher scoring substrates are tested 
using an assay to confirm the inhibition.15,16   
 
 
5.1 | DOCK Blaster.  The screening platform chosen for molecular screening of the LuxS 
enzyme for the discovery of more potential non-SRH analog inhibitors is DOCK Blaster.  
DOCK Blaster is a program created by the Shoichet lab from the University of California, 
San Francisco.  It is available free of charge online, which allows easy access from any 
computer.  DOCK Blaster can also be completely automated, therefore allowing for 
accessibility to the more general public without being an expert in computational chemistry.  
The ZINC database is linked to DOCK Blaster and acts as a self-analysis for the molecule 
docked.  It re-docks the substrate (SRH) and docks decoys onto the active site in order to 
score the molecule on its pose-fidelity and (%) enrichment.15,16 
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5.1.1 | General Guidelines.  For the docking of a set of small molecules to a protein target to 
proceed, a PDB code for the protein of interest is first required.  The PDB codes of all known 
protein crystal structure can be retrieved from the RCSB Protein Data Bank (www.rcsb.org).  
The PDB structure is then initially “scored” by DOCK Blaster for its suitability for docking 
(Figure 5.1).  A small molecule docking database from the DOCK Blaster website must be 
selected after the initial scoring of the molecule is complete.  The chosen database (e.g., 
KEGG or Cayman Chemical) will score every ligand it contains into the selected binding site 
of the protein and show its best 200 hits in the results page.  From the results, ligands are 
chosen for in vitro biochemical validation based on score, availability for purchase, and 
affordability. 
 
 
 
 
 
 
 
 
Figure 5.1.1 | DOCK Blaster Scoring.  A sample calibration docking report of LuxS (PDB: 1JVI).  
The docking report shows the pose fidelity (Å, rmsd) and enrichment (% ranked) of the re-docked 
SRH (ligand) to the LuxS enzyme when compared to 100 decoys.  It uses two sampling schemes 
(coarser and finer) to test different ligand orientations and two scoring schemes (Polarized and Normal 
/ AMBER).  Once SRH is properly scored, LuxS is docked with one of two databases for a chance to 
find a high-scoring ligand that will competitively bind in the LuxS active site.  
 
5.1.2 | Closed-form SRH vs. Open-form SRH.  S-D-Ribosyl-L-homocysteine (SRH) is the 
substrate that binds to the LuxS active site.  It is known that SRH is in its linear aldose form 
when bound to the active LuxS.  The compound “2-keto-SRH” is an intermediate between 
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SRH and DPD and is formed in part by the assisted ring opening by H2O at the active site.8 
Since there is no existing protein crystal structure of the LuxS protein with the linear-SRH 
form bound in the active site, the 2-keto-SRH intermediate is used as a substitute.  However, 
a recent investigation has shown that the α- or β- closed-form SRH has greater binding 
affinity (α-SRH more favorable with a binding energy of 47.5 kJ/mol less than the β-SRH) to 
the LuxS protein than the linear aldose form when performing computational screening. 
Hence, crystal structures containing both forms of SRH are used for the computational 
screening experiment.   
 
Figure 5.1.2 | Different Forms of SRH. According to Huang et al., SRH may bind to the LuxS 
enzyme when its ribosyl moiety is either in its α- or β-SRH form or as a linear aldose.  The 2-keto-
SRH is an intermediate in the conversion of SRH to the product DPD and is more favorable to bind in 
the LuxS active site than the closed-SRH forms.8 
 
 
 
5.1.3 | RCSB Protein Data Bank (PDB).  The Protein Data Bank contains all known protein 
crystal structures to date.  It has information on three-dimensional structures of large 
biological molecules, including proteins.  The Protein Data Bank, which can be found at 
www.rcsb.org, is freely available online to any users.  Anyone can simply search for his or 
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her target by typing on the site’s search bar.  Here, typing “S-Ribosylhomocysteine” (SRH) in 
the search bar gives results that are separated based on the organism, X-ray resolution, release 
date, etc. In this case, the organism of focus is Bacillus subtilis.   From the options provided, 
the PDB codes chosen for the docking experiment portion are 1JVI and 1YCL. The 1JVI 
protein structure is from the organism Bacillus subtilis and has a resolution of 2.2 Å with a 
zinc ion at its active site, where the closed-form SRH is bound. The 1YCL protein crystal 
structure from the organism Bacillus subtilis has a 1.8 Å resolution and contains the 2-keto-
SRH substrate, the intermediate of SRH and DPD.  Since there is no crystal structure with the 
linear-SRH (open-form), the 2-keto-SRH is therefore used for computational screening 
because it is the closest in resemblance to the linear-SRH. 
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B 
 
 
 
 
 
 
 
 
 
Figure 5.1.3 | PDB Codes.  (A) Virtual image of the closed-form SRH in the active site of BsLuxS 
(PDB structure 1JVI) shown using PyMOL.  (B) Virtual image of the SRH and DPD intermediate, 2-
keto-SRH in the active site of BsLuxS (PDB structure 1YCL) shown.   
 
 
5.1.4 | Ligand Databases.  For computational screening to proceed using the DOCK Blaster 
program, a database of virtual ligands must be chosen.  Within the DOCK Blaster website, 
there are several databases already available for docking in silico; which means that no 
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library needs to be created.15 Three databases were chosen to run the experiment.  The first 
database is KEGG.  The reason why the KEGG database is chosen is because it contains the 
closed-SRH within its database, which allowed for a control experiment in the case of 
docking to the 1JVI LuxS crystal structure (see Figure 5.1.3A).22  DOCK Blaster is able to 
dock the closed-SRH from the KEGG database back onto the LuxS active site, which 
demonstrated that the docking run is working correctly, while also providing ligands with 
better scores than the closed-SRH.  Cayman Chemical is the second database where the LuxS 
enzyme is docked, this is due in part that the project goal is to find commercial substrates.  
Cayman Chemical is a widely known company to purchase substrates from and it guarantees 
us that the resulting substrates are truly purchasable.31  Lastly, the FDA database was used for 
docking, however, to date the results from this database have not yet been tested.  
Nevertheless, the FDA database was chosen specifically for the purpose the substrates 
available within its database were already approved as potential drugs.31    
 
 
5.1.5 | Docking Visualization using PyMOL.  PyMOL is a program that is widely used in 
the chemistry community, and it can be freely downloaded for academic purposes.  PyMOL 
provides 3D images of proteins and, in this case, provides a visual image of whether the 
inhibitor has indeed bind to the active site in silico.  The DOCK Blaster results can be 
directly opened and viewed through PyMOL, allowing us to see how every single docked 
result binds to the active site. 
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5.2 | Docking Results.   From the docking of the 1JVI and 1YCL PDB codes, results were 
given from the ZINC database through the DOCK Blaster site.  Some results from the two 
docked PDB codes overlapped, while others docked for one PDB code and did not dock for 
the other PDB code. The results are scored based on how well a ligand docks onto the LuxS 
active site compared to the original SRH substrate.  The substrate results vary in structure.  
There are structures that contain halogens or phosphate groups that are known to be 
indicators for a good competitive inhibitor drug.  The majority of the docking results were 
proven to be non-purchasable or were considered purchasable as  “make on demand”, which 
was considered inaccessible as well (see Appendix A).  The affordability for those “hit” 
compounds that are purchasable such as argininosuccinate and L-NAME are priced at around 
twenty dollars. 
!56 
Table 5.2 | 1JVI vs. 1YCL.  Results obtained from the docking of both 1JVI and 1YCL PDB codes.  Table shows the similarities and difference in 
substrate results obtained from both PDB codes. 
 
! !
Compound Name/ Zinc ID/ CAS # 
Chemical Structure 
1JVI 
Rank / Score 
1YCL 
Rank / Score 
Argininosuccinate / 1529646 / CAS# 918149-29-8 
 
 
15/ –66 7 / –94 
L-NAME/ 15987659 / CAS# 2149-70-4 
 
 
 
19/ –64 x 
N-nitro-L-arginine/ 19796052 / CAS# 2149-70-4   
 
 
 
29/ –62 54 / –75 
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N-amido-L-aspartate / 4096031 / CAS# 6133-30-8L-aspartate / 4096031 / 
CAS # 6133-30-8aspartate / 4096031 / CAS# 6133-30-8L-aspartate/ 
4096031 / CAS# 6133-30-8 
 
 
35 / -62 156 / –67 
(S)-(-)-2-Guanidinoglutaric Acid / 1529598 / CAS# 73477-53-9 
 
 
44 / –61 117 / –69 
Phospho-L-arginine Trisodium Salt / 1530092 / CAS# 1189-11-3 
 
 
67 / –59 2 / –97 
+H2N
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-OOC
H2N
COO-
H2N
HN
COO-
NH2+
COO-
P
HN
HN
COO-
NH2+
+H3N
O
-O
-O
!58 
 !
NG-Hydroxy-L-arginine / 13558688 / CAS# 53598-01-9 
 
 
67 / –59 2 / –97 
S-Ribosyl-L-homocysteine / 4096144  
 
 
 
126 / –55 
(Re-docked) x 
Pteroic acid / 18182503 / CAS# 119-24-4 
 
 
 
x 104 / –70 
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5.2.1 | KEGG Database Results.   Two docking runs were performed on the 1JVI PDB 
codes in order to test whether there would be a difference in in the outcome of structures 
given.  As can be seen in the two sections that follow, the scoring between the “Faster” and 
“Slower” run of DOCK Blaster onto the KEGG database differs in the way they are scored.  
This is due to the carefulness of scoring of each substrate and how it is bound to the active 
site.  The faster a substrate is scored the less likely it could be scored appropriately; however, 
for the purpose of these initial investigations, the “Faster” scoring is sufficient in giving 
results.  Running the slower run is less agreeable because of the amount of time it takes for 
docking to complete.15 Further testing on the results from the slower run needs to be done in 
the future since majority of the results were never tested in order to obtain an accurate 
observation on whether the results given from the slower run are better.  The only result from 
the slower run that was tested using the inhibition assay was Sulfasalazine, which later was 
proven to be an unreliable source since the substrate itself colored the solution yellow, 
confounding the Ellman’s assay readout.  Therefore, Sulfasalazine was not a suitable test 
subject for the comparison between the “Faster” and “Slower” run of the KEGG database.  
To date, all of the leading substrates that showed inhibition were results obtained from the 
faster run of the KEGG database 
 
 
5.2.1.1 | Initial Results. For the initial run performed from query #72834 (PDB code 1JVI 
using faster scoring), the pose fidelity (Å, rmsd) and enrichment (% ranked) for the re-
docking of SRH ranks at the very top with no other substrates ranking higher, as can be seen 
by the table result given by DOCK Blaster shown below.  When the molecules from the 
KEGG database were docked into the 1JVI structure, SRH was identified as a result, ranking 
at 126.  This not only means that the screening results are likely reliable, but also that 125 
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substrates identified in silico may potentially bind better than SRH to the LuxS active site. A 
full listing of these hit compounds is included in Appendix A. Interestingly, a number of 
these 125 “hit” compounds had structures similar to that of the amino acid arginine. These 
compounds and their screening scores are shown in the table below.    
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DOCK Blaster > 1JVI < KEGG Database > Faster Run < 72834 
Name of Compound Compound Structure Score 
 (kcal/mol ) / 
Rank 
N-nitro-L-arginine 
 
 
 
 –62/!29 
Argininosuccinate 
 
 
 –66/!15 
 
 
L-Nitroarginine methyl 
ester hydrochloride  
(L-NAME) 
 
 
 –64/!19 
S-Ribosylhomocysteine 
(SRH) - control 
 
 
 –55/!126 
 
 
5.2.1.2 | Second-Round Results.  The results obtained from the slower run of the 1JVI PDB 
code, Job I.D. #63945 did not score the SRH as a potential inhibitor.  It gives higher negative 
scores than the faster run.  At least one arginine-related compound was identified in this 
screen. However, to date only the substrate Sulfasalazine was ever tested from this run and it 
was judged to be a very invalid substrate to test because it turned the solution yellow, which 
interfered with the monitoring of the actual inhibition since the 2-nitro-5-thiobenzoate that is 
being monitored is yellow.  Therefore, further testing needs to be conducted in order to 
determine whether results obtained from the slower run are more accurate compared to the 
faster run.  
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DOCK Blaster > 1JVI < KEGG Database > Slower Run < 63945 
Name of Compound Compound Structure Score 
 (kcal/mol ) / 
Rank 
2'-Deoxyguanosine-5'-
monophosphoric acid 
disodium salt 
 
 
 
–970/ 34 
Sulfasalazine 
 
 
 
–950 / 46 
 
 
 
 
5.2.2 | Cayman Chemical Database Run Results.  Selected DOCK Blaster results from the 
1JVI PDB code run, query run #67436 using the Cayman Chemical database are shown 
below.  Since SRH is a non-commercial compound, it is to be expected that it would not be 
within the Cayman Chemical database and therefore this positive control is not available.  On 
a positive note, when docking through Cayman Chemical, the results given are known to be 
purchasable through the Cayman Chemical website. This screen gave a variety of new 
structures, many of which remain to be validated in vitro. (For the full collection of query 
#67436 hits, see Appendix A.) 
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Table 5.2.2 
DOCK Blaster > 1JVI< Cayman Chemical > 67436 
Name of Compound Compound Structure Score 
 (kcal/mol ) / 
Rank 
D-Propargylglycine 
 
 
 
–43 / 24 
6,7-
Dimethyltetrahydropterin 
(hydrochloride) 
 
 
–42 / 28 
 
 
6-Hydroxy 
Chlorzoxazone 
 
 
–34 / 96 
Niflumic Acid 
 
 
–34/ 112 
Gefitinib 
 
 
–32/ 146 
Biopterin 
 
 
–47 / 11 
 
 
5.2.3 | FDA Database Run Results.  From the same DOCK Blaster 1JVI PDB code run 
result, query run # 63945, the FDA database was also run.  The database was chosen for the 
purpose that substrates that were obtained from this database are FDA approved. Although 
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the FDA database was run, none of the substrates have yet been tested.  This is due to results 
from previous structures that showed promise and therefore, more assays were done from 
substrates that were more similar to results (such as argininosuccinate and L-NAME). 
 
 
Table 5.2.3 
DOCK Blaster> 1JVI < FDA > 67436 
Name of Compound Compound Structure Score 
 (kcal/mol ) / 
Rank 
Levodopa 
 
 
 
–50 / 6 
L-Leucine 
 
    
 
–50 / 5 
 
 
Eflornithine 
Hydrochloride 
 
 
–35 / 42 
5-Fluoro-2'-
deoxyuridine 
 
         
 
 
–34 / 49 
 
 
5.3 | Conclusion and Future Directions.  The future goal for the docking portion of this 
project is to continue to dock the LuxS proteins (1JVI or 1YCL) using other molecule 
databases that could lead to more arginine-based substrates that were not initially discovered 
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in the KEGG and Cayman Chemical database as well as to test the inhibitors that were given 
as a result from the FDA database and other interesting candidates that have not yet been 
assayed.  In the hopes that more promising leads come from DOCK Blaster, similar structure 
searches from inhibitors that showed promise from the Ellman’s assay could be conducted to 
find a competitive inhibitor that would significantly be better than those that have already 
been reported. 
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Chapter 6: Selection and in vitro Testing of Potential Competitive 
Inhibitors of LuxS 
 
 
Inhibition assays are common methods to observe whether a potential new inhibitor has 
successfully inhibited its target site in an enzyme of interest.  There are different types of 
enzyme inhibition, such as uncompetitive inhibition, mixed inhibition, non-competitive 
inhibition, and competitive inhibition.  In this project, the goal is to search for potential 
competitive inhibitors of the enzyme LuxS through computational screening.  Selected “hit” 
results from in silico experiments (Chapter 5) were tested in vitro using a colorimetric assay 
called an Ellman’s assay.  It was expected that if a result from the computational screening 
were to competitively bind to the active site of the LuxS enzyme, then the activity of the 
enzyme would decrease and hence, less colored product is produced under Ellman’s assay 
conditions. 
 
 
6.1 | Competitive Inhibition.  The goal of the project is to discover new potential 
competitive inhibitors of LuxS that are non-SRH analogs.   Competitive inhibition is a type of 
inhibition in which an inhibitor binds to the same active site as an enzyme’s substrate; in this 
case the substrate is SRH.  Both the substrate and inhibitor cannot be bound to the enzyme’s 
active site at the same time.  Either the substrate or inhibitor (or neither) is bound to the active 
site.  Competitive inhibition is reversible; however, in the case of a potent competitive 
inhibitor it would take high concentrations of substrate, beyond that typically available in 
vivo, to overcome the inhibition.  In competitive inhibition, the maximum velocity (Vmax) is 
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unchanged; however, since the substrate is less favorable to bind at the active site, the Kd will 
decrease and hence, KM will increase.14  
    
 
6.1.1 | General Guidelines for Inhibition Assays.  The preparation of an inhibition assay 
includes a potential inhibitor that was a result from a reliable DOCK Blaster run (see Chapter 
5).  Again, the goal of the project is to search for purchasable potential competitive inhibitors 
that are non-SRH analogs.  The assay also needs the 1.6 µM purified LuxS enzyme (see 
Chapter 4), 34 µM SRH substrate, 150 µM Ellman’s reagent (DTNB), 5× LuxS Buffer, and 
deionized water.  Competitive inhibition is dose-dependent, and therefore increasing amounts 
of inhibitor are added to each of a series of cuvettes during the assay.  The inhibitor 
concentrations used for the assays are 68 µM, 136 µM, 204 µM, 272 µM, and 340 µM.   
 
 
 
6.2 | DOCK Blaster Hit Categories.  For each docking of the B. subtilis LuxS 1JVI and 
1YCL PDB code, 200 potential inhibitors result.  The 1JVI PDB code was docked with the 
KEGG database, the Cayman Chemical database, and FDA database, whereas 1YCL was 
only docked with the KEGG database (see Chapter 5).  Below is a table that shows the 
compounds that were results from DOCK Blaster that have, to date, been tested in vitro.  The 
docking of the 1JVI and 1YCL PDB code gave results that showed promise such as 
argininosuccinate and L-NAME.  Initially, N-nitro-L-arginine and argininosuccinate were 
tested for inhibition.  The results from these assays can be seen below.  N-Nitro-L-arginine 
shows minimal inhibition; however, argininosuccinate produced data that showed more 
pronounced inhibition in initial trials. Hence, another arginine-based structure, L-NAME, 
which was a lower-ranking DOCK Blaster hit, was also tested.  The IC50 from the L-NAME 
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Ellman’s Assay run showed that it was even more competitive than argininosuccinate.  From 
these results, it was decided that since both substrates showed inhibition from the Ellman’s 
assay, a similarity structure search of arginine would be thoroughly investigated and if 
permitted, tested. 
 
 
 
6.2.1 | Arginine-Based Structures.  DOCK Blaster results that were tested and showed 
similarity in its foundation as the amino acid, Arginine are shown below.  The scoring of 
these arginine-based structures are relevant in that L-NAME showed the most significant 
inhibition when compared to argininosuccinate and when argininosuccinate is compared to N-
nitro-L-arginine. 
 
DOCK Blaster> Results 
Name of Compound Compound Structure Score (kcal/mol) 
/ Rank 
N-Nitro-L-arginine 
 
 
 
 
–62 / 35 
Argininosuccinate 
 
 
 
–60 / 44 
 
 
L-Nitroarginine 
methyl ester 
hydrochloride  
(L-NAME) 
 
 
 
–59 / 60 
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6.2.1.1 | Similarity Structure Searches.  From the DOCK Blaster results that gave 
promising inhibition results, a similar structure search was done on N-nitro-L- arginine and 
argininosuccinate.  The similar structure searches were done using Sigma-Aldrich structure 
search and SciFinder.  Those that do not have a similar structure score were chosen logically 
based on its similarity in structure to arginine.  These results can be seen in the tables below. 
 
6.2.1.1.1 | SciFinder Similarity Searches. 
Similar Structure Search> SciFinder< Results 
Name of Compound Compound Structure Similarity Score 
L-Glutamine 
 
 
 
 
 
83 
L-Arginine 
hydrochloride 
 
 
 
82 
 
 
 
6.2.1.1.2 | Sigma-Aldrich Similarity Searches. 
Similar Structure Search> Sigma-Aldrich< Results 
Name of 
Compound 
Compound Structure Similarity 
Score 
NG-Methyl-L-
arginine acetate 
salt  
  
 
 
 
 
50 
NG, NG- 
Dimethylarginine 
dihydrochloride  
  
 
 
 
50 
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6.2.1.1.3 | Other Structural Types.  Other amino acids that may be the closest in structure 
similarity to Arginine are also investigated to see whether others will show greater inhibition 
than Arginine. 
 
Similar Structure Search> Arginine-based< Results 
Name of Compound Compound Structure Similarity Score 
L-Lysine 
  
 
 
 
 
-- 
D,L-Asparagine 
  
 
 
 
-- 
 
 
Succinic Acid 
 
 
 
-- 
 
 
6.3 | Assays of Selected Compounds.  The inhibitors that have been tested thus far are N-
nitro-L-arginine, argininosuccinate, L-NAME, succinic acid, L-glutamine, L-arginine 
hydrochloride, NG-methyl-L-arginine acetate salt, NG, NG- dimethylarginine dihydrochloride, 
D,L- asparagine, and L-lysine.  The inhibitors were chosen based on its availability for 
purchase, affordability, and its similarity to the arginine structure.  The inhibitors were results 
of screening in silico and / or of similarity structure searches. 
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6.3.1 | Argininosuccinate and Similar Structures.  From the initial findings of the Ellman’s 
assay for argininosuccinate, which gave an IC50 of 490 µM for this in silico screening “hit”, it 
was determined that the focus of the project will continue to look into arginine-based 
compounds. Therefore, structures similar to it were also tested.  NG-Methyl-L-arginine 
acetate salt and NG, NG- dimethylarginine dihydrochloride are two of a few structures that are 
given from the similar structure search of argininosuccinate through Sigma–Aldrich and that 
were actually assayed to determine if inhibition is occurring.   
 
 
6.3.1.1 | Argininosuccinate.  The first promising result that came from DOCK Blaster was 
argininosuccinate.  Argininosuccinate was dissolved to a final stock concentration of 680 µM 
with 5× LuxS Buffer and deionized water.  As described in section 2.4.2, the cuvette 
contained 5× LuxS Buffer, deionized water, 34 µM SRH, 1.6 µM Co-BsLuxS-HT enzyme, 
DTNB, and increasing concentrations of argininosuccinate.  The LuxS inhibition assay of 
argininosuccinate was measured at 412 nm at increasing inhibitor concentrations using 68 
µM, 136 µM, 204 µM, 272 µM, and 340 µM of argininosuccinate.  The assay was done in 
triplicate and graphed using GraphPad Prism.  Below shows the results in slopes of the linear 
regression fits of each concentration of inhibitor used in the assay as well as the standard 
error. In all cases, the y-intercept of the linear regression approximates zero. 
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A 
 
B 
 LuxS [1.6 µM] Only SRH [34 µM] Only LuxS [1.6 µM] + SRH [34 µM] 
Slope 1.0 (± 0.01) × 10–4 7.5 (± 3.0) × 10–6 5.9 (± 0.11) × 10–4 
 
 LSI [68 µM] LSI [136 µM] LSI [204 µM] LSI [272 µM] LSI [340 µM] 
Slope 4.5 (± 0.067) × 10–4 4.3 (± 0.077) × 10–4 4.2 (± 0.092) × 10–4 3.9 (± 0.050) × 10–4 3.3 (± 0.095) × 10–6 
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 LuxS [1.6 µM] 
Only 
LuxS [1.6 µM] 
+ SRH [34 µM] 
LSI [68 µM] LSI [136 µM] LSI [204 µM] LSI [272 µM] LSI [340 µM] 
Standard 
Error 
0.067 0.58 0.33 0.33 0.33 0.33 0.33 
 
Figure 6.3.1.1 | Argininosuccinate Inhibition Assay.  Dose-dependent inhibition trials for argininosuccinate.  (A) Average of 3 LuxS inhibition assay 
runs using argininosuccinate as the possible inhibitor.  The error bars given on the graph are in standard error of 3 trials.  (Legend: LSI = LuxS + SRH + 
Inhibitor , closed circle = Buffer Blank, closed square = LuxS[1.6 µM] only, closed triangle = SRH[34 µM] only, closed inverted triangle = LuxS[1.6 
µM] + SRH[34 µM], closed diamond = LSI[68 µM], open circle = LSI[136 µM], open square = [204 µM], open triangle = LSI[272 µM], and open 
inverted triangle = LSI[340 µM]) (B) Shows the best-fit line for each subject using argininosuccinate as the inhibitor.  C) Slopes from each LuxS 
inhibition run used to compare the activity under different concentrations of succinic acid.  The column is produced from the average slope of each 
subject from all 3 trials.  Error bars that are on the graph are the standard error of 3 trials for each subject. ! !
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6.3.1.2 | NG-Methyl-L-arginine acetate salt.  NG-Methyl-L-arginine acetate salt (L-NMMA) 
was a Sigma–Aldrich result from a similarity structure search using argininosuccinate as the 
initial structure.  NG-Methyl-L-arginine acetate salt was dissolved with 5× LuxS buffer to 
achieve a 1 M stock concentration.  A typical LuxS inhibition assay for NG-Methyl-L-
arginine acetate salt consist of 5× LuxS Buffer, deionized water, 34 µM SRH, 1.6 µM Co-
BsLuxS-HT enzyme, Ellman’s reagent (DTNB), and increasing concentrations of inhibitor.  
Concentrations of the inhibitor tested are 68 µM, 136 µM, 204 µM, 272 µM, and 340 µM and 
measured at 412 nm.  The results were then graphed on GraphPad Prism. 
 
 
 
 !!
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A 
 
B  
 LuxS [1.6 µM] Only SRH [34 µM] Only LuxS [1.6 µM] + SRH [34 µM] 
Slope 1.6 (± 0.049) × 10–4 –1.7 (± 0.56) × 10–5  5.1 ± (0.11) × 10–4 
 
 LSI [68 µM] LSI [136 µM] LSI [204 µM] LSI [272 µM] LSI [340 µM] 
Slope 4.9 (± 0.22) × 10–4 4.5 (± 0.11) × 10–4 3.3 (± 0.061) × 10–4 3.2 (± 0.042) × 10–4 2.4 (± 0.48) × 10–4 
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 LuxS [1.6 µM] 
Only 
LuxS [1.6 µM] + 
SRH [34 µM] 
LSI [68 µM] LSI [136 µM] LSI [204 µM] LSI [272 µM] LSI [340 µM] 
Standard 
Error 
0.33 0.27 0.81 0.32 0.30 0.26 0.27 
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D  
 
IC50 [µM] LogIC50 [µM] 
540  2.7 
 
Figure 6.3.1.2 | NG-Methyl-L-arginine acetate salt (L-NMMA) Inhibtion Assay.  To determine 
whether NG-methyl-L-arginine acetate salt is a competitive inhibitor of LuxS by performing dose-
dependent inhibition assays.  (A) Graph of the average of (3) LuxS inhibition assay runs using NG-
methyl-L-arginine acetate salt as the possible inhibitor.  The error bars given on the graph are in 
standard error of (3) trials.  (Legend: LSI = LuxS + SRH + Inhibitor, closed circle = Buffer Blank, 
closed square = LuxS[1.6 µM] only, closed triangle = SRH[34 µM] only, closed inverted triangle = 
LuxS[1.6 µM] + SRH[34 µM], closed diamond = LSI[68 µM], open circle = LSI[136 µM], open 
square = [204 µM], open triangle = LSI[272 µM], and open inverted triangle = LSI[340 µM])  (B) 
Shows the best-fit line for each subject using NG-methyl-L-arginine acetate salt as the inhibitor.  C) 
Compares the activity of the enzyme by using the slopes obtained from each LuxS inhibition run, 
which uses different concentrations of NG-methyl-L-arginine acetate salt.  D) The IC50 graph of NG-
methyl-L-arginine acetate salt.  The column is produced from the average slope of each point from all 
3 trials.  
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6.3.1.3 | NG, NG- Dimethylarginine Dihydrochloride.  NG, NG- dimethylarginine 
dihydrochloride was another Sigma–Aldrich result from a similarity structure search using 
argininosuccinate as the desired structure.  NG, NG- Dimethylarginine dihydrochloride was 
dissolved with 5× LuxS buffer to achieve a 1 M stock concentration.  A typical LuxS 
inhibition assay for NG, NG- dimethylarginine dihydrochloride consist of 5× LuxS Buffer, 
deionized water, 34 µM SRH, 1.6 µM Co-BsLuxS-HT enzyme, Ellman’s reagent (DTNB), 
and increasing concentrations of inhibitor.  Concentrations of the inhibitor tested are 68 µM, 
136 µM, 204 µM, 272 µM, and 340 µM and measured at 412 nm.  The results were then 
graphed on GraphPad Prism. 
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A 
 
B  
 LuxS [1.6 µM] Only SRH [34 µM] Only LuxS [1.6 µM] + SRH [34 µM] 
Slope 1.5 (± 0.030) ×!10–4 –1.7 (± 0.29) ×!10–5  5.2 (± 0.12) ×!10–4 
 
 LSI [68 µM] LSI [136 µM] LSI [204 µM] LSI [272 µM] LSI [340 µM] 
Slope 4.3 (± 0.0093) ×!10–4 4.2 (± 0.12) ×!10–4 3.7 (± 0.0067) ×!10–4 2.8 (± 0.004) ×!10–4 3.4 (± 0.0059) ×!10–4 
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 LuxS [1.6 µM] 
Only 
LuxS [1.6 µM] 
+ SRH [34 µM] 
LSI [68 µM] LSI [136 µM] LSI [204 µM] LSI [272 µM] LSI [340 µM] 
Standard 
Error 
0.22 0.36 0.23 0.22 0.62 0.53 0.11 !
Figure 6.3.1.3 | NG, NG- Dimethylarginine Dihydrochloride Inhibition Assay.  Dose-dependent inhibition trials for NG, NG- dimethylarginine 
dihydrochloride.  (A) Average of 3 LuxS inhibition assay runs using NG, NG- dimethylarginine dihydrochloride as the possible inhibitor.  The error bars 
given on the graph are in standard error of 3 trials.  (Legend: LSI = LuxS + SRH + Inhibitor , closed circle = Buffer Blank, closed square = LuxS[1.6 
µM] only, closed triangle = SRH[34 µM] only, closed inverted triangle = LuxS[1.6 µM] + SRH[34 µM], closed diamond = LSI[68 µM], open circle = 
LSI[136 µM], open square = [204 µM], open triangle = LSI[272 µM], and open inverted triangle = LSI[340 µM]) (B) Shows the best-fit line for each 
subject using NG, NG- dimethylarginine dihydrochloride as the inhibitor.  C) Slopes from each LuxS inhibition run used to compare the activity under 
different concentrations of NG, NG- dimethylarginine dihydrochloride.  The column is produced from the average slope of each subject from all 3 trials.  
Error bars that are on the graph are the standard error of 3 trials for each subject.!  
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6.3.1.4 | Succinic Acid.  Succinic acid was a potential inhibitor that was investigated based 
upon its similarity in structure to argininosuccinate (representing approximately one-half of 
the molecular structure).  Succinic acid was dissolved with 5× LuxS Buffer and deionized 
water.  The LuxS inhibition assay for succinic acid includes 5× LuxS Buffer, deionized 
water, 34 µM SRH, 1.6 µM Co-BsLuxS-HT enzyme, Ellman’s reagent (DTNB), and 
increasing concentrations of inhibitor.  Concentrations of the inhibitor tested are 68 µM, 136 
µM, 204 µM, 272 µM, and 340 µM and measured at 412 nm.  The results were then graphed 
on GraphPad Prism.  
 
  
!82 
A 
!
B 
 LuxS [1.6 µM] Only SRH [34 µM] Only LuxS [1.6 µM] + SRH [34 µM] 
Slope 9.2 (± 0.29) ×!10–5 –3.3 ( ± 0.64) ×!10–5 3.6 (± 0.093) ×!10–4 
 
 LSI [68 µM] LSI [136 µM] LSI [204 µM] LSI [272 µM] LSI [340 µM] 
Slope 2.9 (± 0.27) ×!10–4 3.1 (± 0.060) ×!10–4 3.7 (± 0.095) ×!10–4 3.3 (± 0.11) ×!10–4 2.5 (± 1.7) ×!10–4 
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Average of (3) LuxS Inhibition Assay (Succinic Acid)
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A 4
12
Best-fit values
Slope
Y-intercept when X=0.0
LuxS[1.6µM] Only
9.217e-005 ± 2.912e-006
0.0007319 ± 0.0003264
SRH[34µM] Only
-3.259e-005 ± 6.380e-006
-0.002296 ± 0.0007151
LuxS[1.6µM]+
0.0003567 ± 9.337e-006
-0.002860 ± 0.001047
LSI[68µM]
0.0002928 ± 2.650e-005
-0.002550 ± 0.002970
LSI[136µM]
0.0003120 ± 6.019e-006
-0.0001363 ± 0.0006747
LSI[204µM]
0.0003659 ± 9.525e-006
-0.001514 ± 0.001068
LSI[272µM]
0.0003293 ± 1.119e-005
0.0008957 ± 0.001255
LSI[340µM]
0.0002525 ± 1.696e-005
-0.004839 ± 0.001901
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 LuxS [1.6 µM] 
Only 
LuxS [1.6 µM] + 
SRH [34 µM] 
LSI [68 µM] LSI [136 µM] LSI [204 µM] LSI [272 µM] LSI [340 µM] 
Standard 
Error 
0.043 0.28 0.36 0.12 0.26 0.28 0.27 
 
Figure 6.3.1.4 | Succinic Acid Inhibition Assay.  Dose-dependent inhibition trials for succinic acid.  (A) Average of 3 LuxS inhibition assay runs using 
succinic acid as the possible inhibitor.  The error bars given on the graph are in standard error of 3 trials.  (Legend: LSI = LuxS + SRH + Inhibitor , 
closed circle = Buffer Blank, closed square = LuxS[1.6 µM] only, closed triangle = SRH[34 µM] only, closed inverted triangle = LuxS[1.6 µM] + 
SRH[34 µM], closed diamond = LSI[68 µM], open circle = LSI[136 µM], open square = [204 µM], open triangle = LSI[272 µM], and open inverted 
triangle = LSI[340 µM]) (B) Shows the best-fit line for each subject using succinic acid as the inhibitor.  C) Slopes from each LuxS inhibition run used 
to compare the activity under different concentrations of succinic acid.  The column is produced from the average slope of each subject from all 3 trials.  
Error bars that are on the graph are the standard error of 3 trials for each subject.!  
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6.3.1.5| L-Arginine hydrochloride.  L-Arginine hydrochloride was a SciFinder structure 
search result using argininosuccinate as the model of the type of structure desired 
(representing approximately one-half of the molecular structure).  L-Arginine hydrochloride 
was dissolved with 5× LuxS Buffer and deionized water.  A typical LuxS Inhibition assay 
included 5× LuxS Buffer, deionized water, 34 µM SRH, 1.6 µM Co-BsLuxS-HT enzyme, 
Ellman’s reagent (DTNB), and increasing concentrations of inhibitor.  Concentrations of the 
inhibitor tested are 68 µM, 136 µM, 204 µM, 272 µM, and 340 µM and measured at 412 nm.  
The results were then graphed on GraphPad Prism.  
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A 
 
B 
 LuxS [1.6 µM] Only SRH [34 µM] Only LuxS [1.6 µM] + SRH [34 µM] 
Slope 1.2 (± 0.047) ×!10–4 –8.8  (± 7.2) ×!10–6 3.8 (± 0.10) ×!10–4 
 
 LSI [68 µM] LSI [136 µM] LSI [204 µM] LSI [272 µM] LSI [340 µM] 
Slope 3.5 (± 0.14) ×!10–4  
 
3.2 (± 0.086) ×!10–4 3.6 (± 0.056) ×!10–4 3.0 (± 0.12) ×!10–4 2.5 (± 0.12) ×!10–4 
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LuxS[1.6µM] Only
SRH[34µM] Only
LuxS[1.6µM]+SRH[68mM]
LSI[68µM]
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LSI[204µM]
LSI[272µM]
LSI[340µM]
Time(s)
A 4
12
Best-fit values
Slope
Y-intercept when X=0.0
LuxS[1.6µM] Only
0.0001163 ± 4.731e-006
0.001449 ± 0.0005303
SRH[34µM] Only
-8.752e-006 ± 7.222e-006
-0.001635 ± 0.0008096
LuxS[1.6µM]+
0.0003773 ± 1.004e-005
-0.0008974 ± 0.001125
LSI[68µM]
0.0003458 ± 1.375e-005
-0.0008969 ± 0.001541
LSI[136µM]
0.0003244 ± 8.604e-006
0.001801 ± 0.0009644
LSI[204µM]
0.0003587 ± 5.571e-006
0.002138 ± 0.0006245
LSI[272µM]
0.0002996 ± 1.233e-005
0.0002140 ± 0.001382
LSI[340µM]
0.0002520 ± 1.245e-005
-0.0005296 ± 0.001395
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 LuxS [1.6 µM] 
Only 
LuxS [1.6 µM] 
+ SRH [34 µM] 
LSI [68 µM] LSI [136 µM] LSI [204 µM] LSI [272 µM] LSI [340 µM] 
Standard 
Error 
0.013 0.037 0.29 0.21 0.068 0.18 0.19 
 
Figure 6.3.1.5 | L-Arginine hydrochloride Inhibition Assay.  Dose-dependent inhibition trials for L-arginine hydrochloride.  (A) Average of 3 LuxS 
inhibition assay runs using L-arginine hydrochloride as the possible inhibitor.  The error bars given on the graph are in standard error of 3 trials.  
(Legend: LSI = LuxS + SRH + Inhibitor , closed circle = Buffer Blank, closed square = LuxS[1.6 µM] only, closed triangle = SRH[34 µM] only, closed 
inverted triangle = LuxS[1.6 µM] + SRH[34 µM], closed diamond = LSI[68 µM], open circle = LSI[136 µM], open square = [204 µM], open triangle = 
LSI[272 µM], and open inverted triangle = LSI[340 µM]) (B) Shows the best-fit line for each subject using L-arginine hydrochloride as the inhibitor.  C) 
Slopes from each LuxS inhibition run used to compare the activity under different concentrations of L-arginine hydrochloride.  The column is produced 
from the average slope of each subject from all 3 trials.  Error bars that are on the graph are the standard error of 3 trials for each subject. 
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6.3.2 | Other Arginine-Based Structures.  Other arginine-based structures were also 
included among the results from in silico docking experiments using DOCK Blaster.  One of 
the initial results was N-nitro-L-arginine, which showed minimal inhibition in initial trials.  
However, because argininosuccinate showed promising results, the related compound L-
NAME was also tested for inhibition. 
 
 
6.3.2.1 | N-Nitro-L-arginine.  N-Nitro-L-arginine is the first inhibitor tested using the LuxS 
Inhibition Assay.  N-Nitro-L-arginine was dissolved with 0.1 M HCl to a final stock 
concentration of 680 µM.  A typical mixture for a LuxS Inhibition assay includes 5× LuxS 
Buffer, deionized water, 34 µM SRH, 1.6 µM wild-type Co-BsLuxS-HT enzyme, Ellman’s 
reagent (DTNB), and increasing concentration of inhibitor.  The assay is done in triplicate for 
reproducibility and reliability purposes.  The concentrations of N-nitro-L-arginine tested are 
68 µM, 136 µM, 204 µM, 272 µM, and 340 µM.  The dose-dependent inhibition was 
measured at 412 nm and the results are graphed using GraphPad Prism. 
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A 
 
B 
 LuxS[1.6µM] Only SRH[34µM] Only LuxS[1.6µM]+SRH[34µM] 
Slope 1.4 (± 0.010) ×!10–4 1.4 (± 0.46) ×!10–5 6.5 (± 0.22) ×!10–4 
 
 LSI[68µM] LSI[136µM] LSI[204µM] LSI[272µM] LSI[340µM] 
Slope 5.7 (± 0.22) ×!10–4 6.2 (± 0.25) ×!10–4 5.5 (± 0.16) ×!10–4 5.5 (± 0.32) ×!10–4 5.6 (± 0.23) ×!10–4 
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 LuxS [1.6 µM] 
Only 
LuxS [1.6 µM] + 
SRH [34 µM] 
LSI [68 µM] LSI [136 µM] LSI [204 µM] LSI [272 µM] LSI [340 µM] 
Standard 
Error 
0.11 0.46 0.63 0.55 0.34 0.68 0.52 
 
Figure 6.3.2.1 | N-Nitro-L-arginine Inhibtion Assay.  Dose-dependent inhibition trials for N-nitro-L-arginine.  (A) Average of 3 LuxS inhibition assay 
runs using N-nitro-L-arginine as the possible inhibitor.  The error bars given on the graph are in standard error of 3 trials.  (Legend: LSI = LuxS + SRH 
+ Inhibitor , closed circle = Buffer Blank, closed square = LuxS[1.6 µM] only, closed triangle = SRH[34 µM] only, closed inverted triangle = LuxS[1.6 
µM] + SRH[34 µM], closed diamond = LSI[68 µM], open circle = LSI[136 µM], open square = [204 µM], open triangle = LSI[272 µM], and open 
inverted triangle = LSI[340 µM]) (B) Shows the best-fit line for each subject using N-nitro-L-arginine as the inhibitor.  C) Slopes from each LuxS 
inhibition run used to compare the activity under different concentrations of N-nitro-L-arginine.  The column is produced from the average slope of each 
subject from all 3 trials.  Error bars that are on the graph are the standard error of 3 trials for each subject. 
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6.3.2.2 | L-Nitroarginine methyl ester hydrochloride (L-NAME).  L-NAME was a DOCK 
Blaster result from the docking of the 1JVI PDB code, as well as a similarity structure result 
using argininosuccinate as the structure target.  L-NAME was dissolved with 5× LuxS buffer 
to achieve a 1 M stock concentration.  A typical LuxS inhibition assay for L-NAME 
consisted of 5× LuxS Buffer, deionized water, 34 µM SRH, 1.6 µM Co-BsLuxS-HT enzyme, 
Ellman’s reagent (DTNB), and increasing concentrations of L-NAME.  Concentrations of the 
inhibitor tested are 68 µM, 136 µM, 204 µM, 272 µM, and 340 µM and measured at 412 nm.  
The results were then graphed on GraphPad Prism. 
 
 
 !
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A 
 
B 
 LuxS [1.6 µM] Only SRH [34 µM] Only LuxS [1.6 µM] + SRH [34 µM] 
Slope 1.1 (± 0.21) ×10–4 –1.6 (± 1.8)a ×10–5 4.8 (± 0.18) ×10–4 
 
 LSI [68 µM] LSI [136 µM] LSI [204 µM] LSI [272 µM] LSI [340 µM] 
Slope 4.2 (± 0.12) ×10–4 3.6 (± 0.13) ×10–4 3.0 (± 0.14) ×10–4 2.2 (± 0.18) ×10–4 1.9 (± 0.16)!×10–4 
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Figure 6.3.2.2 | L-Nitroarginine methyl ester hydrochloride (L-NAME) Inhibition Assay.  Dose-dependent inhibition trials for L-NAME.  (A) 
Average of 3 LuxS inhibition assay runs using L-NAME as the possible inhibitor.  The error bars given on the graph are in standard error of 3 trials.  
(Legend: LSI = LuxS + SRH + Inhibitor , closed circle = Buffer Blank, closed square = LuxS[1.6 µM] only, closed triangle = SRH[34 µM] only, closed 
inverted triangle = LuxS[1.6 µM] + SRH[34 µM], closed diamond = LSI[68 µM], open circle = LSI[136 µM], open square = [204 µM], open triangle = 
LSI[272 µM], and open inverted triangle = LSI[340 µM]) (B) Shows the best-fit line for each subject using L-NAME as the inhibitor.  C) Slopes from 
each LuxS inhibition run used to compare the activity under different concentrations of L-NAME.  The column is produced from the average slope of 
each subject from all 3 trials.  Error bars that are on the graph are the standard error of 3 trials for each subject. aThis high error value is attributed to the 
inherent uncertainty in fitting what is essentially noise when slope ≈ 0. !
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6.3.3 | Other Amino Acids.  Based on the results that were being obtained from the arginine-
based substrates, it was decided that it would of great interest to examine other amino acids.  
This is to make certain that arginine is the best amino acid to use as a base for drug design for 
the inhibition of the LuxS enzyme.  The other amino acids that were examined were L-
glutamine, L-lysine monohydrochloride, and DL-asparagine.  Below are their Ellman’s assay 
graphs to determine whether they achieved inhibition of the LuxS enzyme. 
 
6.3.3.1 | L-Glutamine.  L-Glutamine was a potential inhibitor that was chosen and 
investigated based on its similarity in structure to L-arginine hydrochloride.  L-glutamine was 
dissolved with 5× LuxS Buffer and deionized water.  The LuxS inhibition assay for L-
glutamine includes 5× LuxS Buffer, deionized water, 34 µM SRH, 1.6 µM Co-BsLuxS-HT 
enzyme, Ellman’s reagent (DTNB), and increasing concentrations of inhibitor.  
Concentrations of the inhibitor tested are 68 µM, 136 µM, 204 µM, 272 µM, and 340 µM and 
measured at 412 nm.  The results were then graphed on GraphPad Prism.   
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A 
 
 
B  
 
 LuxS [1.6 µM] Only SRH [34 µM] Only LuxS [1.6 µM] + SRH [34 µM] 
Slope 1.4 (± 0.041) ×!10–4 –3.9 (± 0.94) ×!10–5 4.6 (± 0.11) ×!10–4 
 
 LSI [68 µM] LSI [136 µM] LSI [204 µM] LSI [272 µM] LSI [340 µM] 
Slope 4.4 (± 0.053) ×!10–4 4.5 (± 0.066) ×!10–4 4.1 (± 0.17) ×!10–4 3.9 (± 0.14) ×!10–4 3.8 (± 0.20) ×!10–4 
 
 
 
!
Average of (3) LuxS Inhibition Assay (L-Glutamine)
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Time(s)
A 4
12
Best-fit values
Slope
Y-intercept when X=0.0
LuxS[1.6µM] Only
0.0001354 ± 4.081e-006
0.001256 ± 0.0004574
SRH[34µM] Only
-3.934e-005 ± 9.447e-006
-0.002827 ± 0.001059
LuxS[1.6µM]+
0.0004599 ± 1.135e-005
0.0006488 ± 0.001273
LSI[68µM]
0.0004408 ± 5.362e-006
0.001090 ± 0.0006010
LSI[136µM]
0.0004450 ± 6.629e-006
0.001812 ± 0.0007431
LSI[204µM]
0.0004112 ± 1.714e-005
0.001721 ± 0.001921
LSI[272µM]
0.0003887 ± 1.420e-005
0.001403 ± 0.001591
LSI[340µM]
0.0003759 ± 1.963e-005
0.001144 ± 0.002201
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C  
 
 LuxS [1.6 µM] 
Only 
LuxS [1.6 µM] 
+ SRH [34 µM] 
LSI [68 µM] LSI [136 µM] LSI [204 µM] LSI [272 µM] LSI [340 µM] 
Standard 
Error 
0.075 0.14 0.089 0.11 0.37 0.27 0.43 
 
Figure 6.3.3.1 | L-Glutamine Inhibition Assay.  Dose-dependent inhibition trials for L-glutamine.  (A) Average of 3 LuxS inhibition assay runs using 
L-glutamine as the possible inhibitor.  The error bars given on the graph are in standard error of 3 trials.  (Legend: LSI = LuxS + SRH + Inhibitor , 
closed circle = Buffer Blank, closed square = LuxS[1.6 µM] only, closed triangle = SRH[34 µM] only, closed inverted triangle = LuxS[1.6 µM] + 
SRH[34 µM], closed diamond = LSI[68 µM], open circle = LSI[136 µM], open square = [204 µM], open triangle = LSI[272 µM], and open inverted 
triangle = LSI[340 µM]) (B) Shows the best-fit line for each subject using L-glutamine as the inhibitor.  C) Slopes from each LuxS inhibition run used 
to compare the activity under different concentrations of L-glutamine.  The column is produced from the average slope of each subject from all 3 trials.  
Error bars that are on the graph are the standard error of 3 trials for each subject. !
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6.3.3.2 | L-Lysine monohydrochloride.  L-Lysine monohydrochloride was a structure tested 
based on its similarity to L-arginine hydrochloride, in the hopes that it would prove that the 
arginine-based structures are unique and important to the inhibition of Co-BsLuxS-HT 
enzyme.  L-lysine monohydrochloride was dissolved with 5× LuxS buffer to achieve a 1 M 
stock concentration.  A typical LuxS inhibition assay for L-lysine monohydrochloride 
consisted of 5× LuxS Buffer, deionized water, 34 µM SRH, 1.6 µM Co-BsLuxS-HT enzyme, 
Ellman’s reagent (DTNB), and increasing concentrations of L-lysine monohydrochloride.  
Concentrations of the inhibitor tested are 68 µM, 136 µM, 204 µM, 272 µM, and 340 µM and 
measured at 412 nm.  The results were then graphed on GraphPad Prism. 
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A 
 
B 
 LuxS [1.6 µM] Only SRH [34 µM] Only LuxS [1.6 µM] + SRH [34 µM] 
Slope 1.3 (± 0.26) ×!10–4 2.0  (± 0.78) ×!10–5 3.9 (± 0.12) ×!10–4 
 
 LSI [68 µM] LSI [136 µM] LSI [204 µM] LSI [272 µM] LSI [340 µM] 
Slope 3.2 (± 0.14) ×!10–4 3.0 (± 0.18) ×!10–4 1.9 (± 0.23) ×!10–4 1.8 (± 0.28) ×!10–4 2.2 (± 0.20) ×!10–4 
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Average of (3) LuxS Inhibition Assay (L-Lysine, monohydrochloride)
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C  
 
 LuxS [1.6 µM] 
Only 
LuxS [1.6 µM] 
+ SRH [34 µM] 
LSI [68 µM] LSI [136 µM] LSI [204 µM] LSI [272 µM] LSI [340 µM] 
Standard 
Error 
0.28 0.030 0.071 0.17 0.35 0.42 0.27 
 
Figure 6.3.3.2| L-Lysine monohydrochloride Inhibition Assay.  Dose-dependent inhibition trials for L-lysine monohydrochloride.  (A) Average of 3 
LuxS inhibition assay runs using L-lysine monohydrochloride as the possible inhibitor.  The error bars given on the graph are in standard error of 3 
trials.  (Legend: LSI = LuxS + SRH + Inhibitor , closed circle = Buffer Blank, closed square = LuxS[1.6 µM] only, closed triangle = SRH[34 µM] only, 
closed inverted triangle = LuxS[1.6 µM] + SRH[34 µM], closed diamond = LSI[68 µM], open circle = LSI[136 µM], open square = [204 µM], open 
triangle = LSI[272 µM], and open inverted triangle = LSI[340 µM]) (B) Shows the best-fit line for each subject using L-lysine monohydrochloride as 
the inhibitor.  C) Slopes from each LuxS inhibition run used to compare the activity under different concentrations of L-lysine monohydrochloride.  The 
column is produced from the average slope of each subject from all 3 trials.  Error bars that are on the graph are the standard error of 3 trials for each 
subject. !
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6.3.3.3 | DL-Asparagine.  DL-Asparagine was another structure that was evaluated based on 
its similarity to L-arginine hydrochloride.  This was in the hopes that it would prove that 
arginine-based structures are the fundamental basis for the discovery of a potential 
competitive inhibitor for the Co-BsLuxS-HT enzyme.  DL-Asparagine was dissolved with 5× 
LuxS buffer to achieve a 1 M stock concentration.  A typical LuxS inhibition assay for DL-
asparagine consist of 5× LuxS Buffer, deionized water, 34 µM SRH, 1.6 µM Co-BsLuxS-HT 
enzyme, Ellman’s reagent (DTNB), and increasing concentrations of DL-asparagine.  
Concentrations of the inhibitor tested are 68 µM, 136 µM, 204 µM, 272 µM, and 340 µM and 
measured at 412 nm.  The results were then graphed on GraphPad Prism. 
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A 
 
 
 
 
 
 
 
B 
 LuxS [1.6 µM] Only SRH [34 µM] Only LuxS [1.6 µM] + SRH [34 µM] 
Slope 2.0 (± 0.28) ×!10–4 3.3  (± 5.3)a ×!10–6 4.4 (± 0.52) ×!10–4 
 
 LSI [68 µM] LSI [136 µM] LSI [204 µM] LSI [272 µM] LSI [340 µM] 
Slope 3.6 (± 0.33) ×!10–4 2.9 (± 0.16) ×!10–4 2.8 (± 0.13) ×!10–4 2.5 (± 0.15) ×!10–4 2.1 (± 0.16) ×!10–4 
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 LuxS [1.6 µM] 
Only 
LuxS [1.6 µM] + 
SRH [34 µM] 
LSI [68 µM] LSI [136 µM] LSI [204 µM] LSI [272 µM] LSI [340 µM] 
Standard 
Error 
0.18 1.0 0.63 0.012 0.20 0.13 0.30 
 
Figure 6.3.3.3 | DL-Asparagine Inhibition Assay.  Dose-dependent inhibition trials for DL-asparagine.  (A) Average of 3 LuxS inhibition assay runs 
using DL-asparagine as the possible inhibitor.  The error bars given on the graph are in standard error of 3 trials.  (Legend: LSI = LuxS + SRH + 
Inhibitor , closed circle = Buffer Blank, closed square = LuxS[1.6 µM] only, closed triangle = SRH[34 µM] only, closed inverted triangle = LuxS[1.6 
µM] + SRH[34 µM], closed diamond = LSI[68 µM], open circle = LSI[136 µM], open square = [204 µM], open triangle = LSI[272 µM], and open 
inverted triangle = LSI[340 µM]) (B) Shows the best-fit line for each subject using DL-asparagine as the inhibitor.  C) Slopes from each LuxS inhibition 
run used to compare the activity under different concentrations of DL-asparagine.  The column is produced from the average slope of each subject from 
all 3 trials.  Error bars that are on the graph are the standard error of 3 trials for each subject. aThis high error value is attributed to the inherent 
uncertainty in fitting what is essentially noise when slope ≈ 0. !
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6.3.4 | Other Structural Types.  As mentioned previously, the 1JVI PDB code was docked 
onto the KEGG database a second time using the slower run.  One of the results given from 
the slower run, Job I.D. #63945 docking, was Sulfasalazine. Sulfasalazine was dissolved with 
5× LuxS buffer to achieve a 1 M stock concentration.  The components in a typical LuxS 
inhibition assay for sulfasalazine includes 5× LuxS Buffer, deionized water, 34 µM SRH, 1.6 
µM Co-BsLuxS-HT enzyme, Ellman’s reagent (DTNB), and increasing concentrations of 
inhibitor.  Concentrations of the inhibitor tested are 68 µM, 136 µM, 204 µM, 272 µM, and 
340 µM and measured at 412 nm.  The results were then graphed on GraphPad Prism, 
however, it was concluded from the very beginning that sulfasalazine was not an ideal 
inhibitor candidate.  This is because sulfasalazine turned out to be yellow in color as a solid 
and then turned yellow in solution.  
 
 !
!10
3 
A 
 
B 
 LuxS [1.6 µM] Only SRH [34 µM] Only LuxS [1.6 µM] + SRH [34 µM] 
Slope 1.4 (± 0.24) ×!10–4 1.3  (± 0.31) ×!10–5 3.9 (± 0.26) ×!10–4 
 
 
 LSI [68 µM] LSI [136 µM] LSI [204 µM] LSI [272 µM] LSI [340 µM] 
Slope 2.9 (± 0.23) ×!10–4 2.8 (± 0.38) ×!10–4 2.7 (± 0.25) ×!10–4 2.7 (± 0.28) ×!10–4 2.4 (± 0.23) ×!10–4 
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LuxS [1.6 µM] 
+ SRH [34 µM] 
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Standard 
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0.11 0.36 0.61 0.66 0.33 0.39 0.68 
 
Figure 6.3.4 | Sulfasalazine Inhibition Assay. Dose-dependent inhibition trials for sulfasalazine.  (A) Average of 3 LuxS inhibition assay runs using 
sulfasalazine as the possible inhibitor.  The error bars given on the graph are in standard error of 3 trials.  (Legend: LSI = LuxS + SRH + Inhibitor , closed circle 
= Buffer Blank, closed square = LuxS[1.6 µM] only, closed triangle = SRH[34 µM] only, closed inverted triangle = LuxS[1.6 µM] + SRH[34 µM], closed 
diamond = LSI[68 µM], open circle = LSI[136 µM], open square = [204 µM], open triangle = LSI[272 µM], and open inverted triangle = LSI[340 µM]) (B) 
Shows the best-fit line for each subject using sulfasalazine as the inhibitor.  C) Slopes from each LuxS inhibition run used to compare the activity under different 
concentrations of sulfasalazine.  The column is produced from the average slope of each subject from all 3 trials.    Error bars that are on the graph are the 
standard error of 3 trials for each subject.!
!
M]
 O
nly
µ
Lu
xS
[1.
6
M]µ
M]
 + 
SR
H[
34
µ
Lu
xS
[1.
6
M]µ
LS
I[6
8
M]µ
LS
I[1
36
M]µ
LS
I[2
04
M]µ
LS
I[2
72
M]µ
LS
I[3
40
0
1
2
3
4
5
Sl
op
e 
(Δ
A
41
2/
Δ
S)
×
  1
04
Mean
Std. Deviation
Std. Error
LuxS[1.6µM] Only
1.361
0.1842
0.1064
LuxS[1.6µM] + SRH[34µM]
3.934
0.6274
0.3622
LSI[68µM]
2.868
1.049
0.6057
LSI[136µM]
2.757
1.140
0.6579
LSI[204µM]
2.743
0.5697
0.3289
LSI[272µM]
2.671
0.6786
0.3918
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6.4 | Determination of IC50.  The IC50 values were determined for substrates that showed 
promise in inhibition of the LuxS enzyme from the Ellman’s assay.  It was imperative that the 
IC50 was determined so that it can be seen how much of the potential inhibitor is needed to 
inhibit the LuxS enzyme by fifty percent.  The IC50 of argininosuccinate and L-NAME were 
calculated and determined.  Equation for the calculation of the IC50 is shown below. 
 
%!!"ℎ!"!#!$%! = !"#$%&!!"#$%$#&! − !"ℎ!"!#$%!!"#$%$#&!"#$%&!!"#$%$#& ×!100% 100! − !%!!"ℎ!"!#!$% = !%!!"#$%$#& 
 
6.4.1 | Argininosuccinate.   Argininosuccinate was the first substrate to have an IC50 graph 
be completed.  However, the graph is not a true triplicate due to the lack of reagent when it 
was initially performed.  The average of three different runs of the Argininosuccinate was 
used to calculate the IC50 average.  
 
 
Figure 6.4.1 | Argininosuccinate IC50 Determination.  The average IC50 of argininosuccinate from 
the three individual run was 490 µM.  Individually, the IC50 of the first trial (Pink) is 400.0 with a 
LogIC50 standard error of 0.036.  The second trial (Turquoise) has an IC50 of 610 with a LogIC50 
standard error of 0.21 and the third trial (Grey) has an IC50 of 450 with a LogIC50 standard error of 
0.16. 
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6.4.2 | L-Nitroarginine Methyl Ester Hydrochloride (L-NAME).  The most promising 
potential inhibitor that was ever tested to date is L-NAME.  Compared to the 
Argininosuccinate, the L-NAME is twice more potent as an inhibitor of LuxS according to 
the Ellman’s assay.  It has an IC50 average of 180 µM.   
 
 
 
IC50 [µM] LogIC50 [µM] 
180  2.2 
 
Figure 6.4.2 | L-NAME IC50 Determination.  The IC50 graph of L-NAME.  The curve is produced 
from the average slope of each point from all (3) trials.  Error bars that are on the graph are the 
standard error of (3) trials for each subject.  
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6.5 | Conclusion and Future Directions.  To date, there have been no other research groups 
known to search for LuxS inhibitors through computational screening.  What is further 
unique to this project is that the screening was done through an automated computational 
screening program called DOCK Blaster, which contains different databases to screen for 
inhibitors.  Using this methodology, it allowed for accessibility for those who do not have a 
broad background in computational chemistry.  The screening gave results that showed 
potential competitive inhibition.  The most promising inhibitor from the screening result to 
this date is compound L-nitroarginine methyl ester hydrochloride (L-NAME), which showed 
an IC50 of 180 µM (Figure 6.4.2) compared to its initial predecessor, argininosuccinate, which 
has an average IC50 of 490 µM.  From the results given by DOCK Blaster, it has been 
demonstrated that searching for potential competitive inhibitors through computational 
screening is viable.  Currently, further testing of other arginine based structures are screened 
through the inhibition assay to determine whether other arginine structures show inhibition of 
quorum sensing system two as well.  Furthermore, future work can be done by continuously 
screening for competitive inhibitors using other databases that are within DOCK Blaster and 
for those who have a background in computational screening, inhibitors can be designed 
manually to fit the LuxS enzyme active site. 
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Appendix A: DOCK Blaster Screening Runs 
 
Results from the docking of 1JVI PDB code: 72834.  The re-docking of the SRH onto the 
LuxS active site showed great results (in green).  This run was done using the faster scheme 
run vs. the slower scheme.  Below is the result page that contains 200 potential inhibitors for 
the LuxS enzyme according the KEGG database.  SRH re-docked as a result from the KEGG 
database, ranking at 126.  Potentially, this means that there are 125 other substrates that could 
potentially bind to the LuxS active site more competitively than the SRH substrate.   
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Results from the docking of 1YCL PDB code: 72887.  The re-docking of the SRH onto the 
LuxS active site showed great results (in green).  This run was done using the faster scheme 
run vs. the slower scheme.  Below is the result page that contains 200 potential inhibitors for 
the LuxS enzyme according the KEGG database.  SRH did not re-dock as a result from the 
KEGG database.   
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Appendix B: LuxS Inhibition Assays 
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N-Nitro-L-arginine Trial 2 
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N-Nitro-L-arginine Trial 3 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 | N-Nitro-L-arginine.  Graphs of all three trials for the LuxS Inhibition assay of N-nitro-L-
arginine. !
!
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Argininosuccinate Trial 1 
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Argininosuccinate Trial 2 
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Argininosuccinate Trial 3 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 | Argininosuccinate.  A triplicate assay of the argininosuccinate was conducted.  Above 
shows all three individual assay. 
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L-Arginine, HCl Trial 1 
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L-Arginine, HCl Trial 2 
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L-Arginine, HCl #2
50 100 150 200
0.00
0.02
0.04
0.06
0.08
Buffer Blank
LuxS[1.6 µM] Only
SRH[34 µM] Only
LuxS[1.6 µM]+SRH[68 µM]
LSI[68 µM]
LSI[136 µM]
LSI[204 µM]
LSI[272 µM]
LSI[340 µM]
Time(s)
A 4
12
!
L-arginine, HCl slope #2
M]
 O
nly
µ
Lu
xS
[1.
6 
M]µ
M]
 + 
SR
H[
34
 
µ
Lu
xS
[1.
6 
M]µ
LS
I[6
8 
M]µ
LS
I[1
36
 M
]
µ
LS
I[2
04
 M
]
µ
LS
I[2
72
 M
]
µ
LS
I[3
40
 
0
1
2
3
4
Sl
op
e 
(Δ
A
41
2/
Δ
S)
×
  1
04
! 162 
L-Arginine, HCl Trial 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 | L-Arginine, HCl.  Graphs of all three LuxS Inhibition assay of L-Arginine, HCl.!!
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2’-Deoxyguanosine-5’-monophosphoric acid disodium salt Trial 1 
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Deoxyguanosine #1 6.13.13
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2’-Deoxyguanosine-5’-monophosphoric acid disodium salt Trial 2 
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Deoxyguanosine #2 6.13.13
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2’-Deoxyguanosine-5’-monophosphoric acid disodium salt Trial 3 
 
 
 
 
 
 
 
 
 
 
Figure 4 | 2’-Deoxyguanosine-5’-monophosphoric acid disodium salt.  Graphs of all three LuxS 
Inhibition assay of 2’Deoxyguanosine-5’-monophosphoric acid disodium salt. !
!
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L-Lysine Trial 1 
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L-Lysine Trial 2 
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L-Lysine #2 8.6.13
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L-Lysine Trial 3 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 | L-Lysine.  Graphs of all three LuxS Inhibition assay of L-Lysine. 
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Succinic Acid Trial 1 
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Succinic Acid Trial 2 
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Succinic Acid #2
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Succinic Acid Trial 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 | Succinic Acid.  Graphs of all three LuxS Inhibition assay of Succinic Acid. !
!
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L-Glutamine Trial 1 
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L-Glutamine #1
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L-Glutamine Trial 2 
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L-Glutamine #2
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L-Glutamine Trial 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 | L-Glutamine.  Graphs of all three trials for the LuxS Inhibition assay of L-Glutamine. !!
!
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NG, NG- Dimethylarginine dihydrochloride Trial 1 
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Dimethylarginine dihydrochloride #1
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NG, NG- Dimethylarginine dihydrochloride Trial 2 
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Dimethylarginine dihydrochloride #2
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NG, NG- Dimethylarginine dihydrochloride Trial 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 | NG,NG- Dimethylarginine dihydrochloride.  Graphs of all three trials for the LuxS 
Inhibition assay of NG,NG- Dimethylarginine dihydrochloride.!!!! !
!
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NG-Methyl-L-arginine acetate salt (L-NMMA) Trial 1 
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L-NMMA #1
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NG-Methyl-L-arginine acetate salt (L-NMMA) Trial 2 
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L-NMMA #2
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NG-Methyl-L-arginine acetate salt (L-NMMA) Trial 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 | NG-Methyl-L-arginine acetate salt (L-NMMA).  Graphs of all three trials for the LuxS 
Inhibition assay of NG-Methyl-L-arginine acetate salt (L-NMMA).!!
!
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DL-Asparagine Trial 1 
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DL-Asparagine #1
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DL-Asparagine Trial 2 
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DL-Asparagine #2
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DL-Asparagine Trial 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 | DL-Asparagine.  Graphs of all three trials for the LuxS Inhibition assay of DL-
Asparagine. 
!
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Sulfasalazine Trial 1 
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Sulfasalazine #1
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Sulfasalazine Trial 2 
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Sulfasalazine #2 7.17.13
0 50 100 150 200
0.00
0.02
0.04
0.06
Buffer Blank
LuxS[1.6 µM] Only
SRH[34 µM] Only
LuxS[1.6 µM]+SRH[68 µM]
LSI[68 µM]
LSI[136 µM]
LSI[204 µM]
LSI[272 µM]
LSI[340 µM]
Time(s)
A 4
12
!
Sulfasalazine slope #2
M]
 O
nly
µ
Lu
xS
[1.
6 
M]µ
M]
 + 
SR
H[
34
 
µ
Lu
xS
[1.
6 
M]µ
LS
I[6
8 
M]µ
LS
I[1
36
 M
]
µ
LS
I[2
04
 M
]
µ
LS
I[2
72
 M
]
µ
LS
I[3
40
 
0
1
2
3
Sl
op
e 
(Δ
A
41
2/
Δ
S)
×
  1
04
! 186 
Sulfasalazine Trial 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 | Sulfasalazine.  Graphs of all three trials for the LuxS Inhibition assay of Sulfasalazine. !
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L-NG-Nitroarginine methyl ester (L-NAME) Trial 1 
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L-NAME Trial #1
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L-NG-Nitroarginine methyl ester (L-NAME) Trial 2 
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L-NAME Trial #2
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L-NG-Nitroarginine methyl ester (L-NAME) Trial 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 | L-NG-Nitroarginine methyl ester (L-NAME).  Graphs of all three trials for the LuxS 
Inhibition assay of L-NAME.!!!
!
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Appendix C: Sample Calculation Preparation 
 
 
 
Sample Calculations for Inhibition Assays. 
 
L-NAME Preparation: !
Ellman’s Reagent (15mM – 1mL stock) 
o 0.005g DTNB 
o 1000 µL 5× LuxS Buffer 
 
5× LuxS Buffer- New Stock (Made 2/19/13) 
o 19.5g of HEPES Sodium Salt (500mM) 
o Adjust to pH 7.0 - HCl 
o 6.5748g of NaCl (750mM) 
 
SRH (680uM- 1000 µL stock)- Made from 20mM stock  
o 200 µL 5× LuxS Buffer 
o 34 µL SRH stock 
o 766 µL ddH2O 
 
Make 1M stock of L-NAME 
0.01g!×  !"!"#.!!!! !× ! !!!!! "# = 37.1 µL of 5×  LuxS Buffer 
 
Make 680 µM stock of L-NAME  
(Stock used in assay) 
(1 M)(x) = (0.00068 M)(2500 µL) 
x = 1.7 µL of 1 M L-NAME stock 
500 µL 5× LuxS Buffer 
1998.3 µL dH2O 
  
Protein LuxS ELS1409 + glycerol (160µM- 120µL stock) – WT-LuxS_KW-2 
(Assuming 1.75mM stock) 
o 10.97 µL 5×  LuxS Buffer 
o 24  µL of ELS1409 (From 1.75 mM stock) 
o 85.03 µL of ddH2O !!!!!
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Appendix D: Sample Activity Calculation for Ellman’s and Inhibition 
Assays 
 
 
 
Sample Calculation for Specific Acitivity in Ellman’s assay or Inhibition assay. !!2.20237!×!10!! !!"! ! !"#∙!"!"###!! !!" !"!!!"# ! !"!!!"#$!∙!"# ! !!!!"""! " ! ! !! "!.!"#!$%&! "   
= 0. 015974 µmol/mg/min 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
 
